Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F7/10—Cooling bags, e.g. ice-bags
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F2007/0001—Body part
  • A61F2007/0052—Body part for treatment of skin or hair
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F2007/0054—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water
  • A61F2007/0056—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water for cooling
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
  • A61F2007/0075—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a Peltier element, e.g. near the spot to be heated or cooled
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F2007/0086—Heating or cooling appliances for medical or therapeutic treatment of the human body with a thermostat
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F2007/0093—Heating or cooling appliances for medical or therapeutic treatment of the human body programmed
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
  • A61F2007/0096—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator with a thermometer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F7/02—Compresses or poultices for effecting heating or cooling
  • A61F2007/0203—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor
  • A61F2007/0215—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor containing liquids other than water
  • A61F2007/0219—Gels

Definitions

• the present disclosure relates generally to systems for cooling tissue.
• several embodiments are directed to treatment systems, methods, and substances for controllably cooling tissue to treat acne or other conditions.
• Exocrine glands found in the skin have a role in maintaining skin health, including lubricating, waterproofing, cleansing and/or cooling the skin or hair follicles of the body by excreting water-based, oily and/or waxy substances through skin pores or hair follicles. Overproduction and/or oversecretion of these substances by certain exocrine glands, such as sebaceous glands and sudoriparous glands (e.g., sweat glands), can cause unappealing skin disorders that have proved difficult to treat.
• sebum a waxy substance produced and secreted by sebaceous glands
• comedones e.g., blackheads, whiteheads, etc.
• other inflammatory conditions of the skin associated with acne e.g., inflamed papules, pustules, nodules, etc.
• Overproducing sebaceous glands associated with hair follicles are mostly found in highly visible regions of the body, such as along the face, neck, upper chest, shoulders and back.
• Hyperhidrosis is a condition associated with excessive sweating caused by the overproduction and secretion of sweat from sweat glands in the skin of mammals. Excessive sweating from eccrine sweat glands, which are distributed almost all over the body, can cause discomfort and embarrassment. For example, focal hyperhidrosis can occur on the palms of the hands, soles of the feet, face and scalp. Apocrine sweat glands, particularly in the axilla (i.e., armpits), have oil-producing cells that can contribute to undesirable odor.
• Treatments for these and other skin and tissue conditions are often ineffective, non-lasting, and/or have undesirable side-effects.
• Figure 1 is a schematic cross-sectional view of the skin, dermis, and subcutaneous tissue of a subject.
• Figure 2 is a schematic cross-sectional view of the skin, dermis, and subcutaneous tissue of the subject in Figure 1 after treating sebaceous glands.
• Figure 3 is a partially schematic, isometric view of a treatment system for non-invasively treating targeted structures in a human subject's body in accordance with an embodiment of the technology.
• Figure 4 is a cross-sectional view of a conduit of the treatment system of Figure 3.
• Figure 5 is a flow diagram illustrating a method for treating a subject's skin in accordance with an embodiment of the technology.
• Figure 6 is a plot of temperature versus time for a treatment involving minimal or no skin supercooling when an applicator is initially placed on a patient's skin to initiate a freeze event.
• Figure 7 is a plot of temperature versus time for a treatment involving substantial skin cooling.
• Figure 8 is a flow diagram illustrating a method for treating a subject's skin in accordance with an embodiment of the technology.
• Figures 9A-9C show stages of a method for preparing a treatment site in accordance with an embodiment of the disclosed technology.
• Figure 10A shows patterned hydrogel suitable for cryotherapy in accordance with an embodiment of the disclosed technology.
• Figures 10B and 10C are plots of propylene glycol concentration versus length for patterned hydrogels.
• Figures 1 1 A and 1 1 B are side views of hydrogel substances with ice nucleating regions in accordance with embodiments of the technology.
• Figure 12A shows an emulsifier or surfactant with a hydrophilic head and a hydrophobic tail.
• Figure 12B shows an agent entrapped by emulsifiers.
• Figures 13A and 13B show an oil-in-water emulsion and a water-in- oil emulsion.
• Figure 14 is a table with melting/freezing point temperatures for fats.
• Figures 15A and 15B show test results performed on skin in accordance with some embodiments of the disclosed technology.
• Figure 16 shows a treatment cycle temperature profile and a temperature response measured by a temperature sensor at an applicator surface- tissue interface.
• Figure 17 shows the temperature of the applicator surface lowered at a constant rate and then held at a generally constant value in accordance with an embodiment of the technology.
• Figure 18 is a plot of temperature versus time showing an exemplary treatment cycle for controlled supercooling and for controlled freezing of tissue by lowering the skin temperature in accordance with an embodiment of the technology.
• Figures 19A-19E are cross-sectional views of an applicator applied to a treatment site and thermal modeling.
• Figures 20A-20F illustrate stages of one method of freezing tissue without supercooling.
• Figure 21 is a plot of temperature versus time for freezing skin multiple times in accordance with an embodiment of the disclosed technology.
• Figure 22A shows an unfrozen liquid coupling media that can serve as an insulator for ice inoculation of skin.
• Figure 22B shows the coupling media of Figure 22A with a shifted temperature profile.
• Figure 23 is a plot of temperature versus propylene glycol (PG) concentration in water in accordance with an embodiment of the disclosed technology.
• Figures 24A-24F show stages of a method for supercooling the skin and then initiating a freeze event in accordance with an embodiment of the disclosed technology.
• Figure 25 is a plot of temperature versus time for supercooling and freezing tissue.
• Figure 26 is a plot of temperature versus time for a procedure that cycles two times to supercool tissue and then triggers a freeze.
• Figures 27A-27C show an applicator and a coupling media at various stages during a procedure.
• Figure 28 shows an applicator applied to a treatment site in accordance with an embodiment of the disclosed technology.
• Figure 29 is a plot of temperature versus time for a temperature profile for triggering ice nucleation by activating an ice nucleator.
• Figure 30 shows an applicator and an ice nucleating agent (INA) applied to a treatment site in accordance with an embodiment of the disclosed technology.
• INA ice nucleating agent
• Figure 31 shows a plot of temperature versus time for delivering an INA for nucleation.
• Figures 32A-32D are IR images showing stages of a process using hydrogel to freeze supercooled tissue.
• Figures 33A-33D are IR images showing tissue freeze inoculation using combined materials.
• Figures 34A and 34B are cross-sectional views of an applicator applied to a treatment site in accordance with some embodiments of the disclosed technology.
• Figure 35 is a plot of temperature versus time for triggering a freeze agent using a hydrogel.
• Figure 36 shows an applicator positioned to produce a controlled freeze in a coupling material in accordance with an embodiment of the disclosed technology.
• Figure 37 shows an applicator with an external nucleating element configured to initiate a freeze event at a location external to an applicator-hydrogel interface.
• Figure 38 is a cross-sectional view of an applicator applied to a treatment site and capable of providing energy-based activation.
• Figure 39 is a plot of temperature versus time for supercooling skin prior to initiating a freeze event.
• Figure 40 is a plot of temperature versus time where, after supercooling and before freezing, a temperature of the applicator is adjusted to warm the epidermis.
• Figure 41 shows a plot of temperature versus time for a cooling protocol and three cross-sectional views of an applicator and skin tissue and temperature distributions.
• Figure 42 shows a temperature profile in the epidermis/dermis and temperature distribution for one treatment protocol.
• Figure 43 shows a temperature profile into the epidermis/dermis for one treatment protocol.
• Figure 44 shows a stage in one method of creating an intradermal tissue freeze using an injectable substance.
• Figure 45 is a flow diagram illustrating a method for preparing and freezing tissue in accordance with an aspect of the present technology.
• Figure 46 is a schematic block diagram illustrating subcomponents of a computing device in accordance with an embodiment of the disclosure.
• the present disclosure describes treatment systems for improving the appearance, function and health of tissue and for performing other treatments.
• Several of the details set forth below are provided to describe the following examples and methods in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them.
• Several of the details and advantages described below, however, may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the technology but are not described in detail.
• Various aspects of the technology are directed to cooling a surface of a patient's skin to produce a cooling event (e.g., a partial freeze event, a total freeze event, etc.) that affects tissue, cells, structures, appendages, or targeted features.
• a cooling event e.g., a partial freeze event, a total freeze event, etc.
• Systems disclosed herein can target glands (e.g., exocrine glands, sebaceous glands, sweat glands, sudoriparous glands, etc.), structures in the skin (e.g., hair follicles, superficial nerves, etc.), and/or layer(s) of tissue (e.g., dermal layer, epidermal layer, subcutaneous layer, sub-layer(s) of the epidermis, dermis, subcutaneous, etc.).
• glands e.g., exocrine glands, sebaceous glands, sweat glands, sudoriparous glands, etc.
• structures in the skin e
• the cooling event reduces or limits overproduction and/or oversecretion of exocrine glands to treat comedones and/or other inflammatory conditions of the skin associated with acne, such as inflamed papules, pustules, nodules, etc.
• the cooling event can cause an effective amount of thermal injury to glands to reduce or limit overproduction and/or oversecretion by those glands to reduce or eliminate acne or other skin conditions.
• the cooling event can include freezing a region of the dermal layer containing the targeted exocrine glands without affecting non-targeted tissue.
• Treatment applicators can be configured for use along the face, neck, upper chest, shoulders, back, and other treatment sites and can target specific layers in the skin, subcutaneous tissue, specific structures, particular cells, etc.
• a method for predictably freezing a subject's skin at a desired predictable time includes lowering a temperature of the skin below a freezing point of fluid in the skin so that the skin is at a first temperature.
• An ice crystal contacts the skin to inoculate the skin and to create a predictable freeze event therein.
• a time of contact between the ice crystal and the skin is controlled so that the predictable freeze occurs at a desired time.
• the method can be performed using an applicator that is applied to the subject's skin.
• a method for freezing dermal tissue more than once while freezing epidermal tissue only once includes applying a coupling media to an applicator.
• the coupling media has a medium therein capable of forming ice crystals.
• a temperature of the applicator is lowered below a freezing point of the medium to at least partially freeze the medium.
• the coupling media, which is carried by the applicator is placed on a subject's skin surface.
• the temperature of the applicator can be adjusted to a treatment temperature for freezing at least a portion of the medium in contact with the skin surface to freeze dermal and epidermal tissue.
• the applicator is warmed an amount sufficient to allow the dermal tissue to thaw but not enough to allow the epidermal tissue to thaw.
• the temperature of the applicator is adjusted to a second treatment temperature such that the at least some of the thawed dermal tissue refreezes and the epidermal tissue remains frozen.
• a method for predictably freezing skin comprises supercooling a subject's skin using a coupling media and an applicator at a first applicator temperature.
• the first applicator temperature is higher than a freezing point of the coupling media.
• the coupling media includes a freezing point depressant which inhibits freezing of the coupling media and the skin.
• the skin is inoculated to freeze the skin without lowering a temperature of the applicator below the first applicator temperature.
• a method for treating skin includes lowering a temperature of a subject's skin below a freezing point of target tissue of the skin. Cooling of the skin is monitored so that freezing therein does not occur. An amount of non-freezing cooling treatment delivered to the skin is controlled so that the target tissue reaches a predetermined first level of cooling. After the target tissue reaches the predetermined first level, the skin is frozen. An amount of freezing cooling treatment delivered to the skin is controlled so that the target tissue reaches a predetermined second level of cooling
• a system for treating a subject includes an applicator configured to cool a subject's skin surface when the applicator is applied to the subject and a controller.
• the controller can be programmed to cause the applicator to, for example, create or maintain at least one ice crystal and/or induce a freeze event in the subject's skin via the at least one ice crystal.
• At least some of the embodiments disclosed herein can be for cosmetically beneficial treatments.
• some treatment procedures may be for the sole purpose of altering a treatment site to conform to a cosmetically desirable look, feel, size, shape or other desirable cosmetic characteristic or feature.
• cosmetic procedures can be performed without providing any or minimal therapeutic effect.
• some treatment procedures may be directed to goals, such as the reduction of acne, that do not include restoration of health, physical integrity, or the physical well-being of a subject.
• methods can target skin irregularities, wrinkles, and sebaceous glands to treat acne; sweat glands to treat hyperhidrosis; hair follicles to injure and remove hair; or other targeted cells to change a subject's appearance or address a condition.
• Treatments may have therapeutic outcomes (whether intended or not), such as, psychological benefits, alteration of body hormone levels (by the reduction of adipose tissue), etc.
• Various aspects of the methods disclosed herein can include cosmetic treatment methods for achieving a cosmetically beneficial alteration of a portion of tissue within the target region. Such cosmetic methods can be administered by a non-medically trained person.
• the methods disclosed herein can also be used to (a) improve the appearance of skin by tightening the skin, improving skin tone and texture, eliminating or reducing wrinkles, increasing skin smoothness, thickening the skin, (b) improve the appearance of cellulite, and/or (c) treat sebaceous glands, hair follicles, and/or sweat glands.
• At least some embodiments of the technology include producing one or more controlled freeze events.
• the location and extent of freezing can be controlled to produce a therapeutic or cosmetic effect.
• Nucleation initiators, nucleation inhibitors, and/or treatment substances can be used before, during, and/or after the freeze event.
• the nucleation initiators can include, without limitation, ice nucleation agents, injectable substances (e.g., saline, ice slurries, etc.), energy that promotes ice nucleation, or other initiators that affect freezing.
• Nucleation inhibitors can include, without limitation, cryoprotectant solutions, freeze temperature depressants, and/or heaters.
• Example substances include thermal coupling gels, cryoprotectant solutions, and/or ice nucleating agents that may be incorporated into or part of a hydrogel material, a liposome, an emulsion, a nano-emulsion, nanoparticle mixture or solution, and/or combinations thereof. Nano-emulsions and nanoparticles may be desirable since their small size makes them suitable to being absorbed into the epidermis and dermis by traveling along hair follicle apertures and/or skin pore apertures.
• a cryoprotectant can be used to enhance the amount of non-freezing treatment to be delivered prior to any freeze event because the cryoprotectant can allow significant supercooling of the skin prior to initiating a freeze event.
• an ice nucleating agent is utilized to reliably and predictably form ice crystals.
• An applicator can predictably freeze targeted tissue or structures by producing a freeze event that occurs in an expected way.
• tissue can be cooled to start a freeze event at an anticipated time (e.g., at a particular time or within an expected period of time), propagate the freeze at a desired rate, achieve a desired extent of freezing, or the like.
• Treatment parameters can be selected based on the desired predictability of the freeze event.
• the skin surface can be cooled to produce a freeze event at least 80%, 85%, 90%, or 95% of the time in a typical patient. This provides a predictable freeze. If a freeze event does not occur, the skin can be warmed and cooled again to produce a freeze event.
• One advantage of freezing is that for a given amount of desired tissue damage, a procedure that produces freezing can take considerably less time than a procedure which does not involve freezing. This is because with freezing, cell walls are damaged.
• Damage to tissue due to freezing and cooling is mainly dependent on, for example, cooling rate, end temperature, holding time (unfrozen and/or frozen), and thawing rate. These variables can be controlled to achieve the desired cryoinjury to target tissue.
• Tissue damage at the cellular scale is known to occur due to intracellular (IIF) and extracellular ice (EIF) formation.
• IIF intracellular
• EIF extracellular ice
• Cryoinjury due to IIF can be accomplished by inducing irreversible damage to the tissues and by necrosis destroying cell organelles and membranes from the inside.
• Cryoinjury due to extracellular ice formation is mainly due to hyperosmolarity in extracellular space and dehydration of the cells because of the extracellular ice. These processes provoke direct cell death or programmed cell death (e.g., apoptosis of the cells).
• Holding time in a frozen state enhances cryogenic tissue injury mechanisms. As ice crystals grow in size during a holding time period, the more they will enhance injury due to IIF and/or EIF.
• Thawing is a destructive factor facilitating recrystallization (ice crystal restructuring), namely, crystals growing bigger, and rehydration of cells causing membrane disruption and cell death.
• Some embodiments are directed to treating tissue below the skin or sublayers or sub-thicknesses of the skin, such as the epidermis, dermis, subdermis, subcutaneous, and sub-layers thereof to treat wrinkles, fine lines, pores, moles, freckles, port wine stains, and other vascular issues, acne, or the like. Additionally or alternatively, treatments can be performed to rejuvenate skin, resurface skin, address skin coloration issues, block pain, etc., and to affect targets, such as appendages, cellular elements, or combinations thereof. Appendages that can be treated include, without limitation, hair follicles, sebaceous glands, sweat glands, arrector pili, nerves, blood vessels, etc.
• Figure 1 is a schematic cross-sectional view of the skin, dermis, and subcutaneous tissue of a subject.
• a subject's skin 10 includes the dermis 12 located between the epidermis 14 and the subcutaneous layer 16.
• the dermis 12 includes sebaceous glands 17 that produce sebum, a waxy substance secreted for moisturizing the skin and hair.
• Acne is a skin condition typically characterized by excess sebum that may plug hair follicles and/or pores.
• the level of sebum production may vary between individuals and may vary by body location depending on the number and sizes of the sebaceous glands. Sebum can flow along the healthy hair follicle 20 to moisturize the hair 23 and/or epidermis 14.
• Hyperhidrosis is characterized by abnormal sweating due to high secretion levels of sweat glands 26.
• Eccrine sweat glands are controlled by the sympathetic nervous system and regulate body temperature. When an individual's body temperature rises, eccrine sweat glands secrete sweat (i.e., water and other solutes) that flows through a gland tubule 28. The sweat can evaporate from the skin surface to cool the body.
• Apocrine sweat glands (not shown) secrete an oil-containing sweat into hair follicles 20.
• the axilla (e.g., armpit) and genital regions often have a high concentration of apocrine sweat glands.
• Hyperhidrosis occurs when sweat glands produce and secrete sweat at levels above that required for regulation of body temperature, and the condition can be generalized or localized (i.e., focal hyperhidrosis) to specific body parts (e.g., palms of hands, soles of feet, brow, scalp, face, underarms, etc.).
• freeze-thaw parameters need to be controlled to achieve predictable therapeutic outcomes. It may be difficult to control freeze-thaw parameters, thus making it difficult to control an amount of treatment. When the amount of treatment is too large, undesirable side effects can occur, such as undesired skin pigmentation changes, and when it is too small, insufficient efficacy can result. This lack of control also can make it difficult to target certain tissue for treatment and to minimize treatment of other specific non-targeted tissue.
• the applicator 104 can accurately target tissue while minimizing or limiting effects on non-targeted tissue. It has been discovered that when an ice crystal contacts skin 10 of the subject at a temperature which is below its phase transition temperature (e.g., melting/freezing temperature) and in a supercooled state, a freeze event can be immediately triggered in the skin. The ice crystal can thus be used to predictably control initiation of the freeze event. Once the freeze event is triggered, it can rapidly propagate through the volume of supercooled tissue. The heat of fusion released during freezing may take the bulk tissue out of its supercooled state, and thereafter the partially frozen skin may prevent non-frozen tissue from reentering a supercooled state.
• phase transition temperature e.g., melting/freezing temperature
• the period of time from the beginning of a freeze event in supercooled tissue to the point where the tissue is largely no longer in a supercooled state may be 1 second, 2 seconds, 3 seconds, 5 seconds, 10 seconds, or another suitable period of time.
• the time period for supercooling can depend on the target location, volume of targeted tissue, supercooled tissue volume, temperature profile, tissue characteristics (e.g., water content of tissue), and/or additives (e.g., compositions, energy, etc.) that may be used as part of the procedure. Because freeze propagation rates may be strongly dependent on the supercool temperature, the temperature of the supercooled tissue can be decreased or increased to increase or decrease, respectively, freeze propagation rates.
• the applicator 104 can be used to precisely control a start time of the freeze event, an amount of damage caused by an initial freeze event (e.g., by controlling an amount of supercooling created prior to initiating the freeze event), a duration of the freeze event (e.g., by controlling a temperature of an applicator), and thawing rate (e.g., start of thaw cycle, etc.).
• the timing of freeze events can be precisely controlled by controlling the generation of the ice crystal and when the ice crystal comes in contact with supercooled skin so that freeze events can be produced "on command," and this control allows for specialized treatment methods to be implemented to controllably and effectively treat a range of tissue while controlling and/or limiting damage to tissue.
• additives can be used to manage freeze events at varying optimum temperatures to target tissue at varying skin depths while controlling tissue damage, extent of injury to non-targeted tissue, etc.
• treatment procedures can target certain tissue without targeting other tissue while also controlling a level of treatment of targeted tissue and effects to non-targeted tissue.
• FIG. 2 shows the skin 10 after a freeze-induced injury has affected the sebaceous glands 17 to reduce or limit sebum production.
• Skin 10 has been frozen to controllably disrupt or injure the sebaceous glands 17 or associated structures which can be an effective treatment for acne.
• the effect to the sebaceous glands 17 is shown while the applicator 104 is applied to the skin 10, it may take a relatively long period of time (e.g., days, weeks, months, etc.) for the glands to be reduced after treatment.
• the sebum production level of the two sebaceous glands 17 in Figure 2, along the hair follicle 22, has been substantially reduced to inhibit clogging to minimize, reduce, or eliminate acne.
• the sweat gland 26 can also be targeted.
• the applicator 104 can produce a partial or total freeze event, non-freezing cooling event, or supercooling event to affect the sweat gland 26 and/or gland tubule 28 in a region of the skin located along the hands, armpits, or other locations with excessive sweat. Other structures in the dermis or other layers of tissue can be targeted. Accordingly, the cold, associated with a controlled freeze generated by the applicator 104, can generally reduce/relieve inflammation associated with acne and be an important treatment pathway. Any and all these pathways of treatment are encompassed by at least one of the embodiments of the technology disclosed herein.
• the surface of the subject's skin can be cooled to produce a temperature at or below -15°C, -10°C, -5°C, 0°C, 5°C, 10°C, 15°C, or 20°C and to produce either a cooling non-freeze event or a freeze event in a targeted portion of the skin.
• Localized freeze events can be generated to affect targeted structures while minimizing, limiting, or substantially preventing thermal injuries to non-targeted tissue, structures, etc.
• Substances used with the applicator 104 can include cryoprotectants, nucleating agents, liposomes, emulsions, hydrogels, combinations thereof, or the like.
• Mechanical energy e.g., massaging
• ultrasound energy e.g., radiofrequency (RF) energy
• freeze initiators can control a freeze event by, for example, initiating, promoting, and/or inhibiting freezing.
• ultrasound energy is delivered to supercooled tissue to trigger freezing in the tissue.
• Radiofrequency energy can be used to warm tissue to isolate freezing to a target region.
• Freeze initiators can be used to initiate a freeze event in the tissue or freeze event in another substance that ultimately causes freezing in the tissue.
• Example freeze initiators include, but are not limited to, one or more water ice crystals, cryoprobes, or substances that rapidly freeze to produce freeze events.
• Freeze events can include partially or completely freezing liquids or lipids proximate to or within cells, and/or structures, to destroy, reduce, disrupt, modify, or affect targeted features.
• the characteristics of the cooling event or freeze event can be controlled to manage thermal injury. Such characteristics include, without limitation, the amount of cooling or freezing, density and distribution of ice crystals, freezing rate, or the like.
• Cryotherapy can affect, without limitation, glandular function, structures of glands (e.g., gland portions, duct portions, etc.), number of glands, sizes of glands, and/or number and/or sizes of cells.
• the freeze event can be maintained for a period of time long enough to elicit a desired result.
• a subject's skin can be cooled to produce a partial freeze event that destroys, reduces, disrupts, modifies, or affects cells or structures of exocrine glands or the supporting anatomical features (e.g., ducts, pores, hair follicles, etc.).
• the level of freezing can be controlled to limit unwanted tissue damage, such as damage to non-targeted tissue, excess damage to targeted tissue (e.g. , to avoid excess damage to targeted tissue), and so forth.
• the skin surface can be continuously or periodically cooled or heated to increase or decrease, respectively, the number and/or sizes of ice crystals at the target region.
• the tissue can be kept in a supercooled state for longer than, for example, about 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, several minutes, or other time period selected to allow the tissue to reach a steady state temperature and desired width, length, and depth of a tissue volume which is in a supercooled state.
• tissue Once tissue is frozen, it can be kept in a partially or totally frozen state for longer than about, for example, about 1 second, 5 seconds, 10 seconds, 20 seconds, 30 seconds, 1 minute, several minutes, or other time period selected to achieve desired effects, while reducing or limiting undesired effects, such as frostbite or necrosis.
• the applicator 104 can include one or more elements 167 for detecting cooling events, freezing events, supercooling, and so forth.
• the thermal device 109 can be controlled based on the output from the element 167 to cool a temperature-controlled surface 1 1 1 , which, in turn, cools the patient's skin.
• the element 167 can include one or more temperature sensors, pressure sensors, detectors, combinations thereof, or the like. Alternatively, separate sensors can be used to monitor the treatment site.
• FIG. 3 is a partially schematic, isometric view of a treatment system for non-invasively treating targeted structures in a body of a human subject 101 in accordance with an embodiment of the technology.
• the treatment system 100 can include the applicator 104, a connector 103, and a base unit 106.
• the applicator 104 can be applied to acne-prone regions to reduce the temperature of lipid-producing cells residing in or at least proximate to sebaceous glands (e.g., glandular epithelial cells) to lower the amount of secreted sebum and thereby eliminate, reduce, or limit acne.
• the applicator 104 can also cool sweat glands and associated structures to treat hyperhidrosis and can perform other treatment procedures.
• the size and configuration of the applicator 104 can be selected based on the treatment site.
• the connector 103 can be a cord that provides energy, fluid, and/or suction from the base unit 106 to the applicator 104.
• the base unit 106 can include a fluid chamber or reservoir 105 (illustrated in phantom line) and a controller 1 14 carried by a housing 125 with wheels 126.
• the base unit 106 can include a refrigeration unit, a cooling tower, a thermoelectric chiller, heaters, or any other devices capable of controlling the temperature of coolant in the fluid chamber 105 and can be connectable to an external power source and/or include an internal power supply 1 10 (shown in phantom line).
• the power supply 1 10 can provide electrical energy (e.g., a direct current voltage) for powering electrical elements of the applicator 104.
• a municipal water supply (e.g., tap water) can be used in place of or in conjunction with the fluid chamber 105.
• the system 100 can include a pressurization device 1 17 that can provide suction and can include one or more pumps, valves, and/or regulators. Air pressure can be controlled by a regulator located between the pressurization device 1 17 and the applicator 104. If the vacuum level is too low, tissue may not be adequately (or at all) held against the applicator 104, and the applicator 104 may tend to move along the patient's skin. If the vacuum level is too high, undesirable patient discomfort and/or tissue damage could occur. A vacuum level can be selected based on the characteristics of the tissue and desired level of comfort. In other embodiments, the applicator 104 does not use a vacuum.
• An operator can control operation of the treatment system 100 using an input/output device 1 18 of the controller 1 14.
• the input/output device 1 18 can display the state of operation of the applicator 104 and treatment information.
• the controller 1 14 can be communicatively coupled to and exchange data with the applicator 104 via a wired connection or a wireless or an optical communication link and can monitor and adjust treatment based on, without limitation, one or more treatment profiles and/or patient-specific treatment plans, such as those described, for example, in commonly assigned U.S. Patent No. 8,275,442, which is incorporated by reference in its entirety.
• the controller 1 14 can be incorporated into the applicator 104 or another component of the system 100.
• the controller 1 14 can cycle through each segment of a prescribed treatment plan. Segments may be designed to supercool tissue, to nucleate supercooled tissue, to freeze tissue, to thaw tissue, to warm tissue, and so on.
• the power supply 1 10 and the fluid chamber 105 can provide power and coolant to one or more functional components of the applicator 104, such as thermoelectric coolers (e.g., TEC "zones"), to begin a cooling cycle and, in some embodiments, to activate features or modes, such as vibration, massage, vacuum, etc.
• thermoelectric coolers e.g., TEC "zones
• the controller 1 14 can receive temperature readings from temperature sensors, which can be part of the applicator 104 or proximate to the applicator 104, the patient's skin, a patient protection device, etc. It will be appreciated that while a target region of the body has been cooled or heated to the target temperature, in actuality that region of the body may be close, but not equal to, the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the system 100 may attempt to heat or to cool tissue to the target temperature or to provide a target heat flux, a sensor may measure a sufficiently close temperature or heat flux.
• power can be increased or decreased to change heat flux to maintain the target temperature or "set-point" selectively to affect targeted tissue.
• the treatment site can be continuously or intermittently evaluated by monitoring various parameters.
• the skin can be continuously monitored to detect its temperature to determine whether it is in a frozen state, an unfrozen state, or other state.
• the applicator 104 can achieve a level or amount of supercooling at a suitable temperature below, for example, -15°C, -10°C, - 5°C, or 0°C. After achieving a predetermined level of supercooling, the applicator 104 can automatically start a freeze event.
• the freeze event can be detected and/or monitored using the applicator 104 or separate device.
• a level of treatment can be controlled following initiation and/or completion of the freeze event.
• One or more post freeze protocols can be performed to thaw or otherwise thermally affect tissue to allow treatment to be specifically tailored to effectively treat certain targets, and to not treat or minimize treatment of non-targeted tissue.
• post-freeze protocols can be used to inhibit, limit, or substantially minimize permanent thermal injuries.
• post-freeze protocols can include gradually or rapidly warming non- targeted and targeted tissue.
• FIG 4 is a cross-sectional view of the connector 103 taken along line 4-4 of Figure 3 in accordance with at least some embodiments of the technology.
• the connector 103 can be a multi-line or multi-lumen conduit with a main body 179 (e.g., a solid or hollow main body), a supply fluid line or lumen 180a ("supply fluid line 180a"), and a return fluid line or lumen 180b ("return fluid line 180b").
• the main body 179 may be configured (via one or more adjustable joints) to "set" in place for the treatment of the subject.
• the supply and return fluid lines 180a, 180b can be tubes made of polyethylene, polyvinyl chloride, polyurethane, and/or other materials that can accommodate circulating coolant, such as water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and/or any other suitable heat conducting fluid.
• each fluid line 180a, 180b can be a flexible hose surrounded by the main body 179.
• coolant can be continuously or intermittently delivered to the applicator 104 via the supply fluid line 180a and can circulate through the applicator 104 to absorb heat.
• the coolant, which has absorbed heat, can flow from the applicator 104 back to the base unit 106 via the return fluid line 180b.
• the connector 103 can also include one or more electrical lines 1 12 ( Figure 4) for providing power to the applicator 104 and one or more control lines 1 16 for providing communication between the base unit 106 and the applicator 104.
• the connector 103 can include one or more tubes or lines 1 19 for substances to be delivered by the applicator 104.
• the substances can include coupling media, INAs, solutions (e.g., cryoprotectant solutions), or the like.
• FIG. 5 is a flow diagram illustrating a method 140 for treating a subject's skin in accordance with an embodiment of the technology.
• the subject's skin can be cooled below a freezing temperature of fluid in the skin.
• One or more ice crystals can be moved into contact with the skin to create a predictable freeze event therein.
• the time of contact between the ice crystals and skin can be controlled to achieve desired freezing. Details of the method 140 are discussed below.
• the skin can be cooled to lower the temperature of the skin below a freezing temperature of fluid in the skin.
• the temperature of the skin can be lowered to a first temperature that is more than 3°C, 5°C, 7°C, 9°C, 10°C, or 1 1 °C below the melting/freezing temperature of fluid in the skin and can be maintained for a first period of time.
• the skin temperature can be lowered to a second temperature that is lower than the first temperature so as to create an ice crystal.
• the first temperature can be maintained at a constant temperature while creating an ice crystal by, for example, altering the composition of a coupling media.
• the coupling media can freeze and cause ice nucleation in the tissue.
• an ice crystal can contact the subject's skin to inoculate the skin upon contact and to create a predictable freeze event therein.
• the ice crystal can be formed externally by an applicator.
• a catheter or other device can introduce the ice crystal into the subject such that the ice crystal physically contacts tissue to be initially frozen.
• an agent can be cooled and then diluted to produce one or more ice crystals therein.
• the agent can include a cryoprotectant for protecting tissue.
• the concentration of cryoprotectant in the agent can be diluted to raise a melting/freezing point of the diluted agent to a value above a temperature of the cryoprotectant so that formation of the ice crystal does not require that the skin temperature be lowered to a value below the melting/freezing temperature of the cryoprotectant.
• a time of contact between the ice crystal and the skin can be controlled.
• a user can hold the applicator against the skin surface while the ice crystal contacts the skin surface.
• the system can notify the subject or operator to remove the applicator from the subject.
• the applicator can be pulled off the subject to stop the crystal contact.
• the applicator can be warmed to melt the ice crystal at the completion of the desired contact period.
• the temperature of the applicator can be controlled to set the length of ice crystal/tissue contact, as well as the length of the freeze event by detecting the freeze event and further controlling when the temperature of the skin is raised to a temperature above the ice crystal's melting point to stop the freeze event.
• the method 140 can include lowering a temperature of a subject's skin below a melting/freezing point or temperature of target tissue of the skin.
• the applicator 104 can monitor cooling of the skin using the sensor so that freezing therein does not occur.
• the amount of non-freezing cooling treatment delivered to the skin can be controlled so that targeted tissue of the skin reaches a predetermined first level at block 142. After the targeted tissue reaches the predetermined first level, the skin is frozen (block 144).
• the sensor can be used to identify and monitor the freeze event. An ice crystal can come into intimate contact with the supercooled skin during the supercooling period and prior to the time when the beginning of a freeze event is desired to occur, without adverse effects.
• the ice crystal(s) can be brought into contact with the skin to initiate the freeze event, and damage associated with the initial freeze event can be largely proportional to the level or extent of supercooling.
• the freeze event can be maintained for any desired period of time, and after the freeze event, additional freeze events can further affect the tissue.
• the amount of freezing/cooling treatment delivered to the skin can be controlled so that it reaches a predetermined second level. In some treatments, the ice crystal is used to cause freezing of skin in the first level of the supercooled state.
• the predetermined second level when combined with the first level, can be selected to provide a therapeutically effective amount of thermal injury.
• a shallow skin treatment can include contacting the subject's skin with ice crystals while the skin has a bulk temperature just slightly below its melting/freezing point, such as by 0.2°C, 0.5°C, 1 °C, 2°C, or 3°C. There may be minimal to no significant skin supercooling, so that the initial freeze event is small (e.g., a fraction of the tissue initially frozen will be small) and relatively small tissue can be frozen when the initial freeze event occurs. Accordingly, initial tissue damage can be predominately located in the epidermis and upper layer of the dermis, with deeper layers, such as subdermal, fat and muscle tissue, being largely unaffected.
• treatments can be performed on acne-prone regions where damage to subcutaneous tissue may be problematic and undesired.
• additional tissue in the skin will not enter a supercooled state because ice crystals in the skin can inhibit or prevent further supercooling. Further additional incremental cooling can result in predictable incremental freezing, and if minimal depth of treatment is desired, a tissue thaw protocol can be started immediately or very soon following the freeze event.
• the system 100 can also perform deeper treatments, including aggressive and deeper skin treatments, by supercooling targeted tissue and then contacting the targeted tissue with an ice crystal to trigger a freeze event.
• the supercooled tissue can include epidermal tissue, dermal tissue, subcutaneous tissue and can be cooled as much as by 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 12°C, 15°C, 17°C, 20°C, 25°C, 30°C, or 35°C and for a significant period of time, such as 30 seconds or 1 , 2, 3, 4, 5, 7, 10, 12, 15, 20, 25 or more minutes.
• the temperature and treatment period can allow for variable and controlled levels of skin supercooling prior to initiating a freeze event.
• An overall level of treatment can also include multiple treatments, each of which individually delivers a dose which is less than a total dose of treatment to ultimately be delivered.
• device software can be programmed to repeat the supercooling and freeze event cycle a second time, optionally after a tissue rewarming/thaw step between cycles. Temperatures and the treatment period for the second cycle can be the same as those of the first cycle or different. Additional treatment cycles could also be delivered. In this example, it would not be necessary to move the applicator between cycles, and the cycles could optionally be separated by a tissue rewarming/thaw step.
• an additional treatment at any given site could be performed later in the patient procedure after an applicator has treated other tissue sites.
• an additional treatment could be delivered during a separate patient procedure performed either later the same day as the first treatment, or the next day or several days or a week later, and the procedure could be repeated on a regular basis if desired (e.g., every day, every other day, every week, every month, etc.). Any number of desired follow-on treatments can be performed to achieve sufficient and desired overall levels of tissue treatment to create a desired tissue response.
• the method 140 can be used to perform the treatments disclosed herein, such as the treatments discussed in connection with Figures 1 and 2.
• a freeze event can cause disruption of sebaceous glands to affect sebum production (e.g., decrease or limit sebum production).
• the period of time of contact e.g., time of contact between the subject's skin and ice crystals and/or between the subject's skin and the cooling surface of the applicator
• the systems, components, and acts disclosed herein can be mixed and matched, as discussed in connection with examples 1 -4 below.
• Ice crystals can be formed along an applicator, using temperature programming.
• Water e.g. , droplets of water, a layer containing water, etc.
• the temperature of the applicator surface can be lowered to about -20°C, -15°C, -12°C, or another suitable temperature for generating one or more ice crystals based on water freezing at or below its melting/freezing temperature of 0°C.
• the applicator can be prepped to have ice crystals on its exterior surface to cause a skin freeze event to occur once the applicator contacts the skin surface.
• one or more ice crystals carried by the applicator can physically contact the skin to initiate a freeze event in the skin.
• the ice crystals can physically contact and trigger a freeze event in a coupling media on the skin surface.
• the coupling media freezes, it can cause freezing of the skin surface and subsequent freeze propagation through deeper tissue.
• the coupling media can be absorbed into the skin, and the absorbed coupling media can freeze to cause freezing of the skin.
• Tissue can be slowly or rapidly rewarmed as soon as practicable after a freeze event has occurred to limit, reduce, or prevent damage and adverse side effects associated with the freeze event.
• the skin can be slowly or rapidly warmed as soon as possible to minimize or limit damage to the epidermis.
• the skin is partially or completely frozen for a predetermined period of time and then warmed.
• the applicator 104 of Figure 2 can warm shallow tissue using, for example, thermoelectric elements in the device 109.
• Thermoelectric elements can include Peltier devices capable of operating to establish a desired temperature (or temperature profile) along the surface 1 1 1 .
• the applicator 104 has electrodes that output radiofrequency energy for warming tissue.
• Absorption enhancers, cryoprotectant agents, INAs, and coupling media can be delivered via liposomes, hydrogels, emulsions, or the like.
• Absorption enhancers can increase permeation to affect uptake of, for example, water, INAs, cryoprotectants, etc.
• Skin can be warmed before or during exposure to applied substances to increase uptake into the epidermis, with minimal or limited increased uptake into the dermis due to the dermal-epidermal junction barrier.
• the characteristics of the tissue can be affected by mechanically altering the subject's skin. These characteristics can include absorption characteristics, thermal characteristics, or the like.
• a cryoprotectant For a treatment which does not include freezing and only cooling or supercooling, it is desirable to increase an uptake of a cryoprotectant into the skin to provide maximum protection against the possibility of a non-intended freeze occurring.
• a treatment which is to include freezing it is desirable to increase an uptake of an INA and/or water to increase the possibility of a freeze event being initiated and being initiated at a desired time, and to increase a level of cryoinjury.
• Figure 6 is a plot of applicator temperature versus time for a treatment involving minimal or no skin supercooling when an applicator is initially placed on a subject to initiate a freeze event in accordance with an embodiment of the disclosed technology.
• a freeze event can be initiated upon placement of a frozen applicator surface on the skin.
• the applicator surface e.g., surface 1 1 1 shown in Figure 2
• the applicator surface can be cooled to a temperature of -15°C to form ice crystals thereon.
• the applicator surface can be applied to the treatment site.
• the applicator surface can be warmed at a rate of 0.4°C/s, 0.5°C/s, or 0.6°C/s to a temperature of about -4°C, -3°C, -2°C, -1 °C, 0°C, etc.
• the skin surface, targeted tissue, etc. can be maintained at a temperature of about -3°C, -2°C, -1 °C, 0°C, or 1 °C.
• the applicator can be kept in thermal contact with the skin surface for a first treatment period (e.g. , 2 minutes, 2.5 minutes, 3 minutes, etc., with 2.5 minutes being shown in Figure 6) to cool the skin from an initial temperature (e.g., 33°C) to a lower temperature (e.g., -4°C, -3°C, -2°C, -1 °C, 0°C).
• a first treatment period e.g., 2 minutes, 2.5 minutes, 3 minutes, etc., with 2.5 minutes being shown in Figure 6
• the applicator surface can then be lowered at a desired rate to a temperature for inducing a freeze event.
• the freeze event (indicated by an "*" in Figure 6) can occur while the applicator surface is cooled at a rate of about 0.2°C/s, 0.25°C/s, 0.3°C/s, or other desired rate.
• the applicator surface can be held at a temperature of about -8°C for a second treatment period (e.g., 20 seconds, 30 seconds, 40 seconds, etc.).
• the skin surface temperature can be slightly higher than the temperature of the applicator surface, so the temperature of the applicator surface can be selected to keep the target tissue frozen for a desired freeze period.
• the applicator and skin temperature can be rapidly raised to a normal temperature, such as room temperature or above.
• the applicator can be warmed at a rate of about 1 °C/s, 2°C/s, 2.5°C/s, 3°C/s, or other rate selected to thaw frozen tissue.
• Figure 6 shows the temperature of the applicator raised at a rate of about 2.5°C/s.
• the thawed tissue can include epidermal tissue, dermal tissue, subcutaneous tissue, and/or other tissue. After the tissue is warmed for a warm period, another cryotherapy procedure can be performed at the same or difference site using the same or different treatment parameters.
• a substance can be applied to either the skin, the applicator, or both, and can be used to generate ice crystals.
• the substance can be a coupling media with one or more cryoprotectant agents and can be applied when it is initially at a temperature above its melting point, which can be several degrees below 0°C and lower than a melting/freezing point of fluid in the skin tissue.
• the melting/freezing point of the applied substance can be in a therapeutic skin supercool treatment temperature range or other suitable temperature range. After a predetermined amount of skin supercooling has occurred, the temperature of the applied substance can be lowered to a value below its melting point or temperature to create ice crystals therein to initiate the freeze event in the skin.
• Cryoprotectant agents can comprise propylene glycol, glycerol, polyethylene glycol, combinations thereof, or other biocompatible agents.
• the substance is a cryoprotectant solution with a cryoprotectant agent mixed with water to provide a desired melting/freezing point.
• the concentration of the cryoprotectant agent can be increased to lower the melting/freezing point of the substance.
• characteristics of the substance e.g., melting point, spontaneous freezing point, etc.
• INAs can be incorporated into the substance to, for example, provide predictable initiation of freeze events once the temperature of the substance is lowered below the melting/freezing point of the INA.
• Figure 7 is a plot of applicator temperature versus time for a treatment involving substantial skin cooling in accordance with an embodiment of the disclosed technology.
• the applicator and skin can be cooled at a desired rate (e.g., 0.5°C/s, "TC/s, 2°C/s, etc.) to a supercooled temperature (e.g., -8°C, -10°C, -12°C).
• a freeze event in the skin can be initiated after a supercooling period of about 3 minutes, 4 minutes, or 5 minutes at the supercooled temperature, illustrated as -10°C. During this period, the skin surface and cooled applicator surface can be at substantially the same temperature.
• a cryoprotectant coupling media can help limit thermal injuries to non-targeted tissue and can be disposed at the applicator-skin interface.
• the cryoprotectant coupling media is about 25% by weight or volume propylene glycol (PG) and about 75% by weight or volume water and has a melting or freezing temperature of about -1 1 °C.
• the composition of the coupling media can be adjusted to increase or decrease its melting/freezing point.
• a temperature of the applicator is further lowered to initiate a freeze event.
• Figure 7 shows initiation of the freeze event in the skin while the applicator and skin surface are cooled from about -10°C to about -18°C.
• the level of freeze in the tissue can be maintained while the applicator surface and skin surface are held at a temperature of about -18°C for 10 seconds prior to rapid rewarming.
• Ice crystals can be generated by diluting a precooled coupling media to raise its melting/freezing point.
• the applied substance can be a 25% by volume PG cryoprotectant solution with a melting temperature of -1 1 °C.
• Tissue can be supercooled to a desired temperature (e.g., -8°C, -10°C, -12°C, etc.). After the desired amount of supercooling has occurred, the freeze event can be initiated by further lowering the temperature of the applied substance (e.g., "diving" the temperature) to a temperature of about -18°C so as to freeze the substance.
• a freeze event can be initiated at a target freeze temperature (e.g., -10°C) or at a higher temperature by injecting cold water or another substance into the applied substance at a predetermined location to locally dilute the cryoprotectant concentration to a level whereat the melting point of the coupling media is higher than the target freeze temperature.
• the melting/freezing point of the coupling media can be, for example, close to -1 °C, -0.5°C, or 0°C so that ice crystals form in the diluted substance and initiate a freeze event in the skin.
• Dilution can be with 100% water, water doped with an INA, or another substance, thereby providing consistent and predictable freezes at temperatures as warm as, for example, -1 °C, -2°C, or -3°C.
• a water and ice mixture or a water, ice, and INA mixture can be injected to provide freezes at about a desired temperature (e.g., -1 °C, -0.5°C, etc.).
• This method can be used in conjunction with substantial skin supercooling to initiate a freeze event at relatively warm temperatures, for example -1 °C, -2°C, -3°C, -4°C, or -5°C, by pre- warming the skin after the supercooling period at a lower temperature (e.g., -8°C, - 10°C, or -12°C ) has elapsed, which can significantly reduce or prevent harm to non- targeted tissue, such as the epidermis, as compared to a treatment where the freeze event is started at a lower temperature, such as -10°C or even lower (e.g., -18°C when "diving" is utilized to initiate the freeze event).
• a lower temperature e.g., -8°C, - 10°C, or -12°C
• Example 3 Energy can be used to manage ice crystal formation.
• ultrasound can induce ice crystal formation in the skin and/or a freeze event in the coupling media whether or not the coupling media is only slightly or significantly supercooled.
• ultrasound and INAs can be used together.
• Ultrasound has been used to form ice crystal in aqueous coupling agents.
• a dental cleaning ultrasound probe operated at about 20 kHz and about 25 W forms ice crystals in coupling agents.
• a non-dental ultrasound probe operated at about 20 kHz and 1 W forms ice crystals. Ultrasound with other parameters can be selected based on desired ice crystal formation and/or growth.
• a freeze event triggering or promoting substance can be injected into or near the target region.
• the substance can be partially frozen ice or a water slurry solution that generates an immediate freeze event.
• the epidermis can be rewarmed to a temperature close to 0°C prior to the freeze event, and an injection of saline ice water slurry into the dermis can initiate the controlled freeze under the epidermis.
• Needles, catheters, or injection devices can be introduced into the subject to inject the substance.
• Figure 2 shows an optional catheter 149 that can be introduced into the subject. Once an end portion of the catheter 149 is positioned in the skin 10, the catheter 149 can deliver an ice crystal, ice slurry, or suitable substance in the tissue.
• the catheter 149 can be used to initiate freeze events at any number of treatment sites.
• Various combinations of steps in examples 1 -4 can be combined.
• contact between an ice crystal and the tissue can be delayed until a desired level of skin supercooling is achieved.
• a volume of target skin can be substantially supercooled and then contacted by ice crystals to maximize freeze injury to the skin while minimizing side effects.
• a large amount of prior supercooling can maximize an amount of tissue damage that occurs during the initial freeze event, and can allow non-targeted tissue to be rewarmed to inhibit, limit, or substantially prevent thermal injury to that non-targeted tissue.
• the epidermis can be non-targeted tissue that can be immediately or quickly re-warmed after the freeze event in the targeted tissue, such as the dermis. Warming can limit or minimize an amount of time the epidermis is in a frozen state. This is in contrast to a treatment method whereby little or no supercooling is employed. In this latter case, to obtain a therapeutic level of treatment equivalent to the former case (which utilizes substantial supercooling and substantial fractional freezing during the initial freeze event, since cooling is delivered "top down," via the surface of the skin), the epidermal tissue needs to be maintained in a frozen state longer after the freeze event is initiated, which can exacerbate damage to non-targeted epidermal tissue.
• FIG 8 is a flow diagram illustrating a method 150 for treating a subject's skin in accordance with an embodiment of the technology.
• coupling media can be applied to the treatment site.
• the treatment site can be cooled, and a freeze event can be initiated to at least partially freeze tissue.
• An early stage of the method 150 can include coupling a heat-exchanging surface of an applicator to the subject's skin.
• the heat-exchanging surface can be a temperature-controlled surface (see, e.g., surface 1 1 1 of Figure 2) of a heat-exchanging plate with internal thermal elements (e.g., thermoelectric elements, fluid elements, etc.) or external thermal elements (e.g., thermal elements mounted to the backside of the heat-exchanging plate).
• the temperature-controlled surface can be an interface layer, a dielectric layer, or the like. Additionally or alternatively, a vacuum or suction force can be used to positively couple the patient's skin to the temperature-controlled surface. Coupling the temperature-controlled surface to the subject's skin can also include providing a substance to the patient's skin as is described herein and in commonly assigned U.S. Patent Publication No. 2007/0255362. Details of the method 150 are discussed below.
• the treatment site can be prepared by, for example, mechanically, chemically, or otherwise altering the skin.
• Mechanical alteration can be achieved by brushing or scraping the skin surface intermittently or continuously for a period of time, such as about 30 seconds, 1 minute, 2 minutes, 3 minutes, or a suitable length of time selected based on the desired amount of surface cleaning, permeation, and/or exfoliation (e.g., exfoliation of the stratum corneum).
• permeability of the skin can be adjusted by clearing pores in the stratum corneum, producing and/growing vacuoles (e.g., vacuoles in the epidermis below the stratum corneum), combinations thereof, or the like.
• an adhesive strip can be applied to and removed from the skin to remove uppermost layers of the epidermis, clean the treatment site, increase permeability of the skin, or otherwise prepare the treatment site.
• the uppermost layers of the epidermis are dryer than lower layers, so when the uppermost layers are removed, the exposed lower layers have greater water content so they are more susceptive to being frozen during a procedure designed to freeze tissue, especially when an INA is used to facilitate the freeze.
• Permeability of the skin can also be increased by using microneedling whereby a plurality of microscopic holes are formed in the skin to create pathways for absorption of a coupling media.
• sonophoresis can be used whereby ultrasound waves are used to stimulate micro-vibrations within the skin to increase the overall kinetic energy of molecules making up the coupling media or topical agent to be delivered into the skin to increase absorption.
• Some preferred frequencies are 20-40 kHz, or more than 1 MHz. Other frequencies could be used.
• increased absorption can be achieved using iontophoresis techniques for increasing absorption using, for example, electric fields to push topical agents into the skin.
• a permeability coefficient of coupling media for passing through tissue e.g., epidermal tissue
• tissue e.g., epidermal tissue
• a permeability coefficient of coupling media for passing through tissue can be increased at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% to achieve desired absorption rates using any one or more of the above described techniques.
• Other techniques can be used to facilitate delivery of coupling media or substances.
• Different testing techniques e.g., static cell techniques, flow-through diffusion techniques, etc.
• algorithms, and modeling can be used to determine the permeability coefficient and can be used to determine flux, including a steady state flux.
• coupling media can be applied to the skin.
• the coupling media can include, without limitation, water, hydrogels, cryoprotectants, emulsions, combinations thereof, or the like before preparing the treatment. Applying the coupling media may include placing, spraying, coating, or rubbing a liquid, gel, or sheet coupling media onto the skin using an instrument including, for example, a brush, a spatula, a spray bottle or a syringe, or by hand (e.g., an operator's gloved hand).
• the coupling media can include one or more temperature depressants, INAs, etc.
• the temperature depressants can include, without limitation, polypropylene glycol (PPG), polyethylene glycol (PEG), propylene glycol, ethylene glycol, glycerol, dimethyl sulfoxide (DMSO), or other glycols.
• the temperature depressants may also include ethanol, propanol, isopropanol, butanol, and/or other suitable alcohol compounds that may lower the freezing point of a solution (e.g., body fluid) to about 0°C to -40°C, and more preferably to about -10°C to -16°C.
• the coupling media can include one or more thickening agents, pH buffers, humectants, surfactants, and/or additives.
• the subject's skin can be cooled.
• An applicator can be applied to the treatment site to place the applicator in thermal contact with target tissue.
• Tissue can be supercooled and then frozen, to limit or prevent unwanted side effects.
• the surface of a human subject's skin can be cooled to a temperature no lower than - 40°C to avoid unwanted skin damage.
• the surface of the skin can be heated to bring shallow non-targeted tissue out of the supercooled state while the deeper targeted region remains in the supercooled state.
• the supercooled targeted region can be nucleated to produce freezing that can destroy or damage targeted cells, for example, due to crystallization of intracellular and/or extracellular fluids.
• a catalyst for nucleation e.g., mechanical perturbations, RF energy, alternating electric fields, etc.
• the mechanical perturbations can be vibrations, ultrasound pulses, and/or changes in pressure.
• Non-targeted layers of tissue can be warmed enough to avoid freezing upon nucleation of targeted tissue.
• the treatment systems disclosed herein can utilize applicators disclosed herein to perform such supercooling methods.
• Some treatments include freezing dermal tissue more times than adjacent epidermal tissue.
• dermal and epidermal tissue can be cooled and frozen (block 158).
• the skin can be warmed by an applicator (which is at a temperature slightly below 0°C) an amount sufficient to allow the dermal tissue to thaw due to internal body heat but not the epidermal tissue which is further removed from blood flow than is dermal tissue.
• block 158 can be repeated by chilling, for example, the skin to refreeze the dermal tissue while the epidermal tissue remains frozen.
• a desired level of damage to the dermal tissue can be achieved by repeatedly freezing and thawing the dermal layer, because the primary mechanism of damage during freezing is caused by ice crystal nucleation and growth.
• Some treatments include a warm/thaw step 159 following the freeze event(s) whereby the frozen and cooled tissue is rewarmed either passively or actively by the applicator.
• the cooling 156 and freezing 158 steps can immediately be repeated, as shown by arrow 153, any number of times, such as 1 , 2, 3, 4 or more times, preferably during the same patient treatment and optionally without moving the applicator.
• the cooling 156 and freezing 158 steps can be repeated during the same patient treatment but after the applicator has been moved to another treatment site and then brought back to the original treatment site, or during a separate patient treatment session either later in the day of the first treatment or the next day or several days later. Any number of repeat sessions can be employed to achieve an overall desired level of treatment.
• Arrows 157 and 155 show possibilities for the retreatment which can include a repeat of the skin preparation step 152 and/or a repeat of the applying coupling media step 154, as desired.
• Figures 9A-9C show stages of a method for preparing a treatment site in accordance with an embodiment of the disclosed technology.
• the subject's skin can be mechanically altered to facilitate absorption of coupling media.
• stripping elements can be applied to and removed from the skin surface any number of times to remove an upper portion of the epidermis so as to expose lower layers of tissue.
• the lower layers can have a relatively high water content and thus may be better able to absorb and uptake various agents, including water or oil based coupling media, into the epidermis.
• Figure 9A is a cross-sectional view of a stripping element 200 applied to the skin surface and overlaying a pore.
• the stripping element 200 can be an adhesive strip (e.g., adhesive tape) or another adhesive element that can be pulled off the skin to remove, for example, sebum, hair follicles, or features from the pilosebaceous unit to expose the skin pore for uptake of applied substances.
• the stripping element 200 may be a single adhesive strip (e.g., piece of adhesive tape) that is cut to overlay the entire treatment area. In other embodiments, multiple stripping elements 200 are applied to the treatment site.
• the adhesive characteristics of the stripping elements can be selected based on the desired amount of mechanical alteration to the skin and desired patient comfort.
• Figure 9B is a cross-sectional view of the stripping element 200 being removed from the skin to remove material 201 from a pore 203 to open or unclog a pore entrance 202. Additionally stripping elements can be reapplied any number of times to further unclog the pore 203 or otherwise prepare the treatment site.
• Figure 9C is a cross-sectional view of a treatment site after the pore 203 has been cleared and a substance 205 has been applied.
• the substance 205 can infuse the pore 203 and can be absorbed by the skin.
• Water can be part of the substance, and a subsequent freeze event can cause the water in the skin pore to freeze and cause additional tissue damage.
• Skin can be mechanically stimulated before, during, and/or after any steps in the method 140 ( Figure 5) or 150 ( Figure 8).
• Mechanical stimulation can include, for example, stimulation or agitation by brushing, rubbing, applying ultrasound, dermabrasion, or other means which can clean the treatment site and/or cause the barrier of the stratum corneum (i.e., the outermost layer of the epidermis consisting of dead cells) to be temporarily reduced and/or increase movement (e.g., turbulence) of the coupling media with respect to the skin.
• mechanical stimulation of the skin can enhance the permeation of the coupling media into the underlying epidermal layer, dermal layer, or another layer of tissue.
• the skin can be mechanically stimulated for about 20 seconds to about 10 minutes.
• mechanical stimulation can be applied to the treatment site for about 20 seconds, about 40 seconds, about 1 minute, about 2 minutes, about 5 minutes or greater than about 5 minutes.
• mechanical stimulation could be performed with, for example, a dermal agitation brush, a brush having rotating bristles, or the like.
• Brushing or rubbing the skin can include, in some embodiments, moving across the skin at the treatment site in a circular or back- and-forth motion or, in other embodiments, in linear strokes, for increasing the skin permeability for the substance.
• the permeation rate can be increased or decreased to achieve a desired amount of absorption.
• the coupling agent can be applied to the treatment site and then cells at the treatment site can be progressively removed by repeatedly applying the stripping element or by applying a series of stripping elements.
• the stripping elements and treatment site can be evaluated to determine the volume of the coupling media absorbed by the skin.
• a substance can be used to improve thermal coupling between a skin surface and a cooling applicator.
• the substance is an aqueous solution coupling agent, which contains a cryoprotectant agent.
• Further substances can contain water and a medium for promoting an on-demand reliable creation of an ice crystal when initiation of freezing in the treatment is desired.
• Liquid water has clusters of molecules that are undergoing constant collisions with other molecules and clusters, sometimes breaking apart and sometimes forming new clusters. When water is being cooled, as the temperature drops and the thermal movement of water molecules decreases, the tendency of water molecules to aggregate becomes stronger and the likelihood that a critically large cluster of molecules will form increases rapidly.
• Ice nucleation is catalyzed upon formation of a critically large cluster of molecules. Consequently, initiation of freeze or ice nucleation in a sample of water (or a coupling agent) takes place from a nucleus with an ice-like structure. The nucleus can promote the organization of water molecules into an ice crystal lattice.
• Water and aqueous coupling agents have a natural tendency to cool to a temperature significantly below their equilibrium freezing point before ice nucleation; that is, they have a tendency to supercool.
• ice nucleation of water There are two modes of ice nucleation of water: homogenous and heterogeneous.
• homogenous When a critically large nucleus is formed by spontaneous aggregation of the water molecules themselves, the nucleation is referred to as "homogeneous.”
• the size of a cluster needed for ice nucleation is often about 25 molecules.
• the radius of the cluster can be about 3 molecules.
• the critical radius that coincides with this size gives a temperature of -41 °C, which is called the homogeneous nucleation temperature for water. Accordingly, the homogeneous nucleation temperature for water is the minimum temperature that pure water can be cooled to before freezing occurs spontaneously.
• the nucleation When aggregation of water molecules is catalyzed by an external source, the nucleation is referred to as "heterogeneous.”
• the cause of external nucleation can be the introduction of ice crystals or another external substance into the supercooled sample.
• crystallization can be triggered by the physical introduction of a nucleation initiator (e.g., a seed crystal or nucleus) around which a crystal structure can form to create a solid.
• the substances can be hydrogels, liposomes, or emulsions, such as oil-in-water (O/W) emulsions, water-in-oil (W/O) emulsions, oil-in-oil (O/O) emulsions, or nano-emulsions, and can provide homogeneous or heterogeneous nucleation.
• O/W oil-in-water
• W/O water-in-oil
• O/O oil-in-oil
• nano-emulsions nano-emulsions
• An INA can be a substance that promotes the formation of a seed crystal (or initial cluster), thus catalyzing a heterogeneous ice nucleation.
• INAs water freezing takes place at a temperature higher than would be required in the case of a homogeneous nucleation, and the largest biological ice nucleators may trigger freezing at -1 °C to -5°C or other lower temperatures, long before a spontaneous water freeze would normally otherwise occur.
• Spontaneous water freezes can variably occur at -10°C, -15°C, -20°C, or -25°C or lower, and the timing of the spontaneous freezes is very unpredictable.
• Example INAs include biogenic-derived proteins, materials derived from a Gram-negative epiphytic bacteria, and/or materials belonging to the genus Pseudomonas, Erwinia, or Xanthomonas.
• INAs may be inorganic- or organic-derived substances that promote heterogeneous ice nucleation.
• Embodiments of the present technology can include methods of producing controlled and predictable freezes of the skin and subcutaneous tissue using INAs.
• INAs can promote the formation of ice crystals in waterlike substances at a specific temperature, such as generally a few degrees below 0°C.
• INAs can be used synergistically with a selected temperature treatment protocol to control the onset and extent of a freeze event during cryotherapy and can be used to promote in-vivo freezing at higher temperatures than a natural homogeneous nucleation freezing point of skin tissue.
• An aspect of some embodiments of the present technology relates to methods of producing a controlled freeze of the skin and subcutaneous tissue using INAs. Cooling methods using INAs permit the triggering of ice nucleation at specific temperatures, such as temperatures close to 0°C.
• INAs may provide an advantage in therapies that require freezing and variable treatment temperatures with desired therapeutic treatment/safe temperature ranges and that create a precise and controllable extent of skin and tissue damage from a freeze event.
• INAs Various Gram-negative epiphytic bacteria have been known to produce INAs. These belong to the genera Pseudomonas, Erwinia and Xanthomonas, among others.
• I NP ice nucleation protein
• Protein molecules and materials located on the outer membrane of these bacteria are responsible for the ice nucleation.
• Cells can also be lysed or otherwise produce pieces of cellular material (e.g., membranes) in which such INAs are found or trapped, for example, Pseudomonas Syringae.
• SNOMAX® available from Snomax LLC, Englewood, Colorado, which is derived from the bacterium Pseudomonas Syringae (freeze-dried protein powder). This protein initiates a freezing process by serving as an ice nucleator and raises the predictable freezing temperature of water to about -3°C.
• SNOMAX® is used widely for snowmaking and is safe for human use and non-pathogenic.
• SNOMAX® can be a powder that exhibits 10 12 to 10 13 ice nuclei per gram at temperatures less than about -4°C.
• Coupling agents prepared with SNOMAX® or other substances derived from the bacterium Pseudomonas Syringae can have enough INAs to produce reliable ice nucleation at desired temperatures. Bacteria/cell concentration has a direct effect on the nucleation temperature of water.
• INAs can be used in standard powder form, and can be used as ice nucleators with or without added water. In some embodiments, INAs can be fractionally delivered to skin, such as by microneedles (e.g., an array of microneedles). Biocompatible INAs can be invasively delivered using needles, such as intradermal needles. Additionally or alternatively, INAs can also be used with non-contact cooling devices, such as cooling/freezing sprays.
• I NAs can be used in cooling protocols to cause ice nucleation at temperatures about -2°C, -3°C, or -4°C. At these temperatures, damage to epidermal tissue can be significantly less than damage typically produced at lower freezing temperatures.
• the temperature for ice nucleation can be selected to be high enough to avoid significant skin pigmentation changes associated with freeze events.
• a non-invasive applicator can be used to control skin cooling and can include one or more temperature sensors. Temperature sensors (e.g., element 167 in Figure 2) can be embedded along the treatment surface of the applicator and can be used as part of a temperature control system.
• the temperature control system can include one or more feedback control algorithms to control the applicator based on a predetermined set of temperature values over one or more predetermined periods of time, and have predetermined rates of change when transitioning from one temperature to another temperature, and so on. Different feedback control algorithms can be used to treat tissue using different treatment temperature protocols (and create different temperature treatment cycles) by varying cooling/thawing rates, predetermining therapeutic treatment temperatures, and/or selecting treatment durations.
• the methods described herein can involve using both INAs to control freezing and varying treatment temperature protocols and profiles.
• An aspect of the present technology relates to methods of using hydrogel substances with freezing point depressants (cryoprotectants) and/or INAs for creating a controlled "on command" predictable freeze.
• Hydrogel substances are a class of crosslinked polymers that, due to their hydrophilic nature, can absorb large quantities of water. Hydrogel substances can have a suitable water content for controlling freezing, including controlling ice nucleation, ice crystallization, freeze propagation, or the like. Integral parts of the hydrogel synthesis include a monomer, an initiator, and a crosslinker.
• Hydrogel properties can be modulated by varying their synthetic factors, such as reaction temperature, monomer type, monomer crosslinker, crosslinker-to-monomer ratio, monomer concentration, and type and amount of initiator.
• the composition of hydrogels can be selected for a specific application by selecting proper starting materials and processing techniques.
• Hydrogels can be mixed with one or more freezing point depressants and can be engineered to have desired melting/freezing temperatures (e.g., optimum melting temperatures).
• the freezing point depressants can inoculate tissue.
• hydrogels can be combined with INAs that have a set activation temperature to make the hydrogels able to freeze consistently at predetermined temperature ranges (or a specific temperature) different from those associated with hydrogels without ice nucleating agents.
• the combination of hydrogels, freezing point depressants, and/or I NAs can result in a controllable freeze at desired temperatures, such as -3°C, -2°C, -1 °C, or other temperatures.
• Temperatures close to 0°C can be less damaging to epidermal tissue and are well suited for less aggressive temperature freezing protocols, so temperatures can be selected to protect one or more upper layers of the skin to eliminate or minimize any substantial discoloration side effects associated with freezing skin treatments and to eliminate any permanent adverse events.
• the water accommodated by the hydrogel structure can be classified in four types: free, interstitial, bound, and semi-bound water.
• Free water is located in the outermost layer and can be easily removed from hydrogels under mild conditions.
• Interstitial water is not attached to the hydrogel network but is physically trapped between the hydrated polymer chains.
• Bound water is directly attached to the polymer chain through hydration of the functional groups or ions.
• the bound water remains as an integral part of the hydrogel structure and can be separated only at very high temperatures.
• Semi-bound water has intermediate properties of bound water and free water. The free and interstitial water can be removed from the hydrogels by centrifugation and mechanical compression.
• Controlled freeze techniques can take advantage of the water composition of hydrogels.
• Hydrogels can be designed to have a specific freezing point or specific freezing temperature range by having a specific ratio of water-monomer- crosslinker content.
• Cryoprotectant additives such as glycols (e.g., PG) or other substances, can be used as well to lower their freezing point.
• a hydrogel can act as an initiator of a predictable freeze event. As the hydrogel freezes, the hydrogel provides "initial seeds” or crystal sites to inoculate tissue and thus catalyze a controlled predictable freeze at a specific temperature in the skin.
• a predictable freeze event can be freezing of tissue that occurs at least 90%, 95%, or 98% of the time when freezing is desired.
• a predictable controlled freeze event in a hydrogel can also be achieved by precooling the hydrogel to a temperature below its melting point.
• the freeze event can be initiated by injecting a nucleation initiator (e.g., ice/water slurry) into the hydrogel to create freezing that reaches the surface of the hydrogel adjacent the patient, which causes freezing of the subject's skin.
• a nucleation initiator e.g., ice/water slurry
• ultrasound or other nucleation energy can be used to produce a freeze event in the hydrogel.
• additives e.g., cryoprotectants and/or I NAs
• cryoprotectants and/or I NAs can be embedded in isolated layers within an interior of the hydrogel so that these substances are not on an exterior surface of the hydrogel sheet or hydrogel pad and hence do not come in direct contact with skin or other tissue being treated. Encapsulating these substances within the hydrogel obviates the need to choose INA substances that have been tested and validated to be safe when in contact with skin or tissue. Predictable hydrogel freezes can be enhanced by additives, such as INAs.
• Figure 10A shows a patterned hydrogel in accordance with an embodiment of the disclosed technology.
• Figures 10B and 10C are plots of PG concentration (%PG) versus length for patterned hydrogels.
• Hydrogels can include a dispersion medium of water and volumes of nucleation inhibitors (e.g., particles or columns of water/PG emulsion).
• Figure 10A shows isolated volumes of nucleation inhibitors spaced apart within a volume of water.
• a hydrogel layer or sheet can contain columns of a nucleation inhibiting emulsion separated by a volume of water with substantially no PG. The water surrounding the columns can serve as ice nucleation sites.
• the inner enclosures can inhibit or prevent diffusion of the water/PG emulsion.
• the composition of the inner enclosure can be selected based on the composition of the enclosed substance, and the pattern, number, and sizes of the localized nucleation inhibiting volumes can be selected based on the hydrogel characteristics.
• Figures 10B and 10C show embodiments with propylene glycol (PG) located throughout the hydrogel, with the concentration of the PG varying along the length and width of a layer or a sheet of hydrogel. Regions of the hydrogel having the lowest concentration of PG have the highest melting/freezing point and can thus function as ice nucleating regions. Isolated freezing zones can be formed in the skin adjacent to those ice nucleating regions.
• Other types of cryoprotectant agents or components can replace PG.
• PG can be replaced or combined with PPG, PEG, DMSO, or the like.
• a further embodiment is a hydrogel that contains an INA placed uniformly throughout areas where it is desired to seed freeze propagation.
• the INA can be dispersed exclusively within interior portions of a volume of hydrogel.
• the INA can be within a hydrogel sheet so that the I NA does not extend to a surface of the sheet, thereby preventing contact between the I NA and the skin.
• the INA can seed a freeze event in an interior region of the hydrogel, and the freeze event can rapidly propagate to an outer surface of the hydrogel, which in turn contacts the skin and causes a freeze event in the skin.
• Figures 1 1 A and 1 1 B are side views of hydrogels with ice nucleating regions.
• Figure 1 1A shows a hydrogel material with an interior ice nucleating region between upper and lower ice nucleating inhibiting regions.
• the ice nucleating region can comprise an INA and can have a relatively low concentration of temperature depressant, if any.
• the ice nucleating region can be substantially free of temperature depressants and can comprise water and ice nucleating features (e.g., I NAs, ice nucleating particles, or the like).
• the ice nucleating region can be a layer, either a continuous layer or as spots on an interior layer so as to be totally embedded within the hydrogel.
• the ice nucleating inhibiting regions can have a melting/freezing point lower than the ice nucleating region and can include volumes of temperature depressants, such as evenly or unevenly spaced apart volumes of PG.
• the pattern, number, and composition of freeze inhibiting features can be selected based on the desired nucleation inhibiting characteristics.
• Figure 1 1 B shows a multilayer hydrogel material with outer ice nucleating inhibiting layers and an inner ice nucleating layer.
• the outer ice nucleating inhibiting layers can include temperature depressants, and the inner layer can comprise a high centration of INA (e.g., mostly INA by volume).
• the outer ice nucleating inhibiting layers can be a layer of a PG solution or a layer with a dense array of PG volumes, and the inner layer can comprise mostly or entirely water.
• a freeze event can be initiated in the ice nucleating layer and then spread through the outer ice nucleating inhibiting layers.
• the hydrogel can be sticky on both a patient side and an applicator side. Sticky upper and lower surfaces can help maintain contact with the subject's skin and applicator and, in some embodiments, help to minimize or limit movement of the hydrogel during treatment.
• a liner can be used to prevent contamination of the hydrogel.
• a side of the hydrogel that contacts a liner can be sticky.
• the hydrogel can be a sheet with a uniform or variable thickness with adhesive applied to one or more of its outer surfaces.
• Hydrogels can be used in the methods discussed in connection with Figures 5, 8, and 9A-9C.
• a hydrogel can be applied to the subject's skin and can include an INA capable of forming ice crystals in the presence of water.
• the INA can be encapsulated within a polymer structure of the hydrogel such that the INA does not come in direct contact with the skin as discussed in connection with Figures 1 1 A and 1 1 B.
• the hydrogel and skin can be cooled to arrive at a suitable cooling temperature for freezing the skin.
• the hydrogel can include a freezing point depressant such that a first melting/freezing temperature of the hydrogel is lower than a second melting/freezing temperature of fluid in the skin.
• skin can be cooled to a temperature above the first freezing temperature and below the second freezing temperature so as to supercool the skin, and after a predetermined amount of supercooling has occurred, the skin is frozen at block 146.
• the temperature of the epidermis can be raised above the first temperature prior to freezing the dermis.
• a hydrogel substance comprising a crosslinked polymer and an INA can be applied at block 154.
• the INA can be embedded within a polymer structure to prevent direct contact between the INA and the skin.
• a sheet of hydrogel can be applied to the subject's skin.
• hydrogel can be injected into the skin.
• Other techniques can be used to apply hydrogels, which can be creams, gels, etc.
• the skin is cooled.
• the freeze event can be initiated using one or more ice crystals. In other embodiments, energy is used to break the structures containing I NAs to release a sufficient amount of the INA to produce a freeze event.
• Liposomal transport of substances into tissue can be used to deliver substances to specific tissue in a more effective manner than by just applying the substances to a surface of the skin. Because a liposome is lipophilic, it can be absorbed at least into the stratum corneum and can then release a substance within the liposome at a specific location or depth in the subject's tissue. Liposomes can trap water in significant "buckets" that enhance the water content of skin when the liposome breaks down, and make freeze protection more predictable when used with significant amounts of cryoprotectant in the water in the liposome. Liposome skin hydration can be more effective than directly applying water to a skin surface since the stratum corneum is normally hydrophobic.
• a topically applied liposome can enhance thermal contact between the applicator/skin and can provide controlled delivery of agents (e.g., cryoprotectant, INAs, etc.), and the liposomes can penetrate the stratum corneum better than either water or water mixed with a cryoprotectant. Additionally, liposomes can deliver different agents to different locations, thus allowing direct transfer of agents to specific targeted cells.
• the liposome contains a cryoprotectant (e.g., propylene glycol) and can break down to release the cryoprotectant.
• the liposome selectively releases an INA to provide controlled freezing capability through specific tissue.
• substances e.g., INAs, cryoprotectant, etc.
• liposomes can be formulated to maintain their structure when penetrating the skin to minimize, limit, or substantially prevent release of substances.
• an "on-command" breakdown of the liposomes can be initiated to trigger a burst release of the embedded agents.
• the liposome can contain an INA for initiating freeze events.
• Triggering methods for breaking down liposomes include using temperature (e.g., temperature cycling), ultrasound, or a cleansing agent to disrupt or break lipid encapsulation of the liposomes.
• An applicator can include heaters for heating the treatment site to cause release of the agents, can include transducers for delivering mechanical energy in the form of ultrasound waves, or can include other elements for disrupting liposomes to perform the methods discussed in connection with Figures 5 and 8.
• Liposomes can have compositions selected based on, for example, a rate of agent release, stability, and/or other desired characteristics.
• the rate of agent release can be increased by applying energy, such as ultrasound, heat, or other energy suitable for breaking down lipids that entrap agents.
• a media can include first liposomes for delivering cryoprotectants to the epidermis and second liposomes for delivering INAs to the dermis. Once the first liposomes are absorbed by the epidermis, they can release the cryoprotectant to protect the epidermis. After the second liposomes have passed through the epidermis and been absorbed by the dermis, they release the INA into the dermal tissue.
• the INA can cause a predictable freeze in the dermal tissue. Accordingly, each agent can be delivered to specific locations using liposomes.
• Liposomal medias can be used before, during, and/or after a treatment session. In some procedures, a topical media is applied to the skin surface to deliver cryoprotectant to shallow tissue before cooling. Another media (e.g., media with an INA) can be injected into deeper tissue once the tissue is cooled and is ready for freezing.
• Emulsions are a class of disperse systems comprising two immiscible liquids and can contain liquid droplets, which comprise the disperse phase, dispersed in a liquid medium, which is the continuous phase.
• Emulsions can be oil-in- water (O/W) emulsions, water-in-oil (W/O) emulsions, oil-in-oil (O/O) emulsions, or nano-emulsions. Nano-emulsions are desirable since they can penetrate the epidermis and dermis along hair follicle apertures and skin pore apertures.
• Figure 12A shows an emulsifier or surfactant with a hydrophilic head and a hydrophobic tail.
• Figure 12B shows an agent (e.g., oil-based agent) entrapped by the emulsifiers to separate the agent and water.
• Figures 13A and 13B show oil-in-water and water-in-oil emulsions.
• the emulsion includes oil droplets that can comprise the same or different agents.
• each droplet can comprise the same agent.
• different agents e.g., dispersed mediums
• the dispersed medium can include droplets containing one or more cryoprotectants, INAs, analgesics, agents, or the like.
• Figure 14 is a table with melting/freezing point temperatures for fats.
• the fats can be natural oils suitable for O/W emulsions and can have relatively high melting points.
• fats can have melting/freeze points above 0°C and can be used in emulsions.
• thermocouple was placed between a coupling layer (coupling media) and skin to detect freezing.
• a coupling layer of only water was tested to confirm there is no freezing of tissue without an INA.
• Figures 15A and 15B show the results of the tests: with INAs the skin was consistently predictably inoculated and frozen three separate times, whereas without INAs the skin tended to merely supercool and not freeze the two separate times an INA was not used.
• Figure 15A shows an example treatment profile designed to supercool at -2°C for 3 minutes and to trigger freezing at -5°C.
• Figure 15B shows three tests with INAs and freeze events occurring shortly after 200 seconds and the associated temperature increase caused by the heat of fusion, which causes the measured temperature to increase from about -1 °C to about 0°C.
• a non-invasive surface cooling apparatus was used to perform the tests discussed in connection with Figures 15A and 15B, and the INA was a SNOMAX®/water solution.
• Figure 16 shows an example treatment cycle temperature profile and a temperature response of the thermal sensor at the applicator surface-tissue interface.
• a target temperature of a temperature-controlled surface of the applicator (shown in dashed line) can be lowered at a predetermined rate and then held constant at a preset value.
• One or more sensors can monitor the temperature at the contact interface. Output from the sensors can be used to precisely control freeze execution in order to maximize cellular changes with a therapeutic purpose while inhibiting, limiting, or minimizing adverse treatment side effects. It may also be desirable to control the extent of skin freezing down to the epidermal-dermal layer, dermal-subcutaneous layer, or other specific depths. A desired freezing extent can be achieved based on knowledge of the freezing point temperature of the bulk tissue.
• exothermic phase change In freeze events, tissue goes through ice nucleation and growth (exothermic phase change).
• An exothermic phase change is when the system releases heat to the surroundings (e.g., changing from a liquid to a solid) during the phase change. Freezing is an exothermic event, releasing heat for a very short time period, and this release of heat can be a reliable indicator of skin freezing.
• Thermal sensors can be used to detect the heat released by the phase change associated with a freeze event.
• a thermal sensor e.g., element 167 in Figure 2
• the released heat is captured by the sensor as a sudden increase of temperature.
• Figure 15B shows temperature increases in tests 2, 3, and 5 corresponding to the released heat.
• Figure 17 shows the set temperature of the applicator surface (shown in dashed line) lowered at a constant rate and then held at a generally constant value.
• the temperature at the applicator-tissue interface is detected by the thermal sensor and shown in solid line).
• a freeze event can be initiated.
• the temperature sensor can detect the temperature increase associated with the heat of fusion, and the detected increase in temperature can be identified as a change in phase.
• Various changes in temperature can be used to monitor tissue and detect phase changes. Some methods can include supercooling and using freezing set points to intentionally treat tissues at subzero temperatures.
• the tissue temperature can be lowered at a desired time during treatment to control onset of freezing.
• Thaw cycles can be included in any treatment cycle to warm tissue at a desired rate for protecting or enhancing tissue injury.
• a treatment cycle can be determined by selecting supercooling parameters, freeze parameters, and thaw parameters.
• the supercooling parameters can include cooling profiles, target temperatures, and/or time periods.
• a cooling profile can include a cooling rate for ramp-down to reach the supercool temperature.
• the target tissue can be kept at a subzero target supercool temperature for the supercool time period without phase change.
• Freeze parameters can include cooling profiles for keeping the tissue in the frozen state and/or time periods for keeping the tissue frozen.
• the freeze parameters can be selected to increase or decrease thermal injury. After completion of the freeze time period, cooled tissue can be warmed using a thawing cycle.
• Supercooling parameters, freeze parameters, and/or thaw parameters can be obtained experimentally ex-vivo and/or in-vivo.
• in-vivo human tests have shown that skin can be supercooled to subzero temperatures, for example, as low as -20°C, without phase change. When the temperature is lowered far enough, the tissue will freeze. It has been experimentally established that human skin tissue will often spontaneously freeze at around -25°C. The temperature of spontaneous freezing depends on the characteristics of the tissue, such as water content of tissue, cellular structure, etc.
• Figure 18 shows an exemplary treatment cycle for controlled supercooling and for controlled freezing. Temperature gradients within tissue during cooling protocols can be estimated by biothermal heat transfer modeling, experimental tests, or a combination of both. Heat transfer modeling can be used to predict the temperature gradients within tissue versus time during a treatment cycle. The volume of tissue, tissue depth, and other information about tissue at subzero temperatures can be calculated.
• a flat applicator can cool skin to supercool targeted tissue between 0°C to -20°C, 0°C to -12°C, 0°C to -10°C, 0°C to -8°C or other suitable temperature ranges to cool targeted tissue to a temperature equal to or lower than about -20°C, -15°C, -13°C, -12°C, -1 1 °C, -10°C, -8°C, -6°C, -5°C, -4°C, -3°C, -2°C, - 1 °C, or 0°C.
• the target tissue can reach a general steady state at which the subject's body heat offsets continued heat withdrawal from the skin surface.
• the temperature- controlled surface of the applicator can be kept at a suitable temperature lower than the desired bulk temperature of the targeted tissue for the supercooling period.
• a temperature of the applicator can be further lowered to ramp down to, for example, a melting/freezing point of a medium on the skin, a freezing point of an agent in the skin, or a freezing point of the skin itself.
• Figures 19A-19E are cross-sectional views of a cooling applicator applied to a treatment site and thermal modeling.
• Figure 19A shows the treatment site at the start of a supercooling cooling cycle when shallow tissue begins to be supercooled.
• Figures 19B-19E show the amount of supercooled tissue increasing over time until the entire epidermis/dermis underlying a cooling plate is supercooled, while the subcutaneous layer is not supercooled.
• Skin tissue that is supercooled is gray, and the non-supercooled tissue is black.
• the supercooled tissue can be at a temperature within a range of about 0°C to -20°C.
• the model for cooling skin is based on a flat plate applicator (with a treatment profile that ramps down at 1 °C/s and a holding step at a target temperature of -20°C) to predict that skin with an epidermal layer of 0.1 mm and a dermal layer of 2 mm, which are above a subcutaneous layer of 1 .0 cm (10mm), can be supercooled completely within 90 seconds.
• skin freeze can be triggered to occur at or after 90 seconds of supercooling.
• skin freeze can be triggered to occur before 90 seconds (for example, after 45, 60, or 75 seconds of supercooling).
• the onset of the freeze event may be delayed for a short period of time (e.g., a few seconds) after the freezing temperature is reached due to the time it takes to cool the tissue to a lower set temperature and the time it takes for an ice nucleation event to occur, so some additional time may need to be added from a time a temperature dive is initiated until a thaw event is begun, to result in a desired amount of time the tissue is in a partially frozen state. For skin, approximately 15 seconds, 20 seconds, or 30 seconds can be average delay times from the beginning of a temperature dive until the freeze event has occurred.
• the entire dermis and epidermis underlying the applicator may not be completely frozen. This is because even at steady state (e.g., when heat extraction by the applicator balances warming from subdermal tissue and blood flow) the bulk temperature of the tissue is not cold enough to absorb all the heat of fusion from the freeze event so as to achieve a 100% tissue freeze. As the heat of fusion is released during the freeze event, the bulk temperature of the tissue rises to a level close to, for example, 0°C such that additional freezing ceases (absent additional significant heat extraction by the applicator) and the skin is only partially frozen when equilibrium is established.
• Figures 20A-20F illustrate stages of one method of freezing tissue without supercooling.
• an applicator can be applied to a treatment site after applying a coupling agent to the applicator and/or treatment site.
• the applicator can freeze a region of the skin while limiting or avoiding supercooling, as discussed below.
• FIG. 20A shows a coupling media 209 (e.g. , water, coupling gel, etc.) located along a temperature-controlled surface 21 1 of the applicator.
• the layer of coupling media can be formed by applying water to the temperature-controlled surface 21 1 , which can be cooled to a temperature less than about -20°C, -15°C, -10°C, or another suitable temperature for freezing most of or all the coupling media 209.
• the temperature-controlled surface 21 1 can then be warmed to a higher temperature (e.g., - 3°C, -2°C, or -1 °C) suitable for applying the applicator to the treatment site.
• a higher temperature e.g., - 3°C, -2°C, or -1 °C
• Figure 20B shows a frozen upper layer 215 and a liquid lower layer 217 of the coupling media after the applicator has been applied to the treatment site 213.
• the warm skin can contact the liquid layer 217 gel while the layer of the frozen coupling media contacts the temperature-controlled surface 21 1 and remains frozen.
• the temperature-controlled surface 21 1 can be held at a temperature suitable for maintaining the frozen upper layer 215 and the liquid lower layer 217.
• Figure 20C shows the temperature-controlled surface 21 1 held at low temperature (e.g., -1 °C, -2°C, -3°C, etc.) for a predetermined period of time to cool the skin to a temperature near its melting/freezing point.
• low temperature e.g., -1 °C, -2°C, -3°C, etc.
• a portion of the coupling media which is frozen may slightly increase in volume, thereby increasing the thickness of the layer 215.
• the temperature of the temperature- controlled surface can be lowered or raised to increase or decrease the thickness of the frozen layer 215 while maintaining a liquid layer 217.
• the temperature-controlled surface 21 1 can be kept at a temperature within a temperature range of about -2°C to about -12°C, about -4°C to about -10°C, or other suitable temperature ranges.
• the temperature-controlled surface 21 1 can be kept at a temperature of about -6°C, -8°C, or -10°C. As the temperature is reduced and/or held a lowered temperature, the freezing front of the coupling media moves towards the skin until substantially all or the entire layer of coupling media/gel freezes.
• Figure 20D shows the entire layer of coupling media 209 in a frozen state.
• the surface of the skin contacting the coupling media 209 can be lowered to its freezing point. Due to the skin's intimate contact with ice crystals in the frozen coupling gel 209, the skin will progressively freeze rather than supercool.
• Figure 20E shows a freezing front 221 and a frozen volume of tissue.
• the freezing front 221 can move deeper into the subject until a desired volume of tissue is frozen.
• Figure 20F shows temperature-controlled surface 21 1 held at a temperature of about -8°C for 2 minutes to produce the enlarged volume of frozen tissue.
• the frozen volume of tissue can stop increasing and become constant when the steady state is established.
• skin can be frozen without affecting underlying muscles and subcutaneous tissue.
• the applicator can freeze skin without affecting subcutaneous tissue to limit or avoid changing skin contours at the treatment site.
• subcutaneous tissue can be frozen to, for example, inhibit, disrupt, or reduce subcutaneous lipid-rich cells to contour the treatment site.
• the applicator can treat acne and can also contour or not contour tissue in a single session.
• the temperature of the temperature-controlled surface 21 1 can be increased to 18°C, 20°C, or 22°C at a rate of 1 °C/s, 2°C/s, or 3°C/s. This will quickly thaw the tissue to minimize or limit further damage to cells.
• the skin can be cooled at a rate of 0.25°C/s, held at a target temperature of -8°C for 2 minutes, and then thawed at a rate of 2°C/s.
• Other cooling rates, target temperatures, and thaw rates can be selected based on the desired level of freezing, thermal injury, etc.
• Targeted tissue can be frozen more times than non-targeted tissue.
• targeted tissue can be frozen multiple times in a single treatment session while freezing non-targeted tissue, such as the epidermis, only one time. Additionally, targeted tissue can be frozen multiple times without supercooling any tissue. In some procedures, the dermis is repeatedly frozen to injure or destroy target glands without repeatedly freezing the epidermis.
• Figure 21 is a plot of temperature versus time for freezing the skin multiple times in accordance with an embodiment of the disclosed technology. After a layer of frozen coupling media is created at -15°C, the temperature-controlled surface of the applicator is warmed to -2°C to cool the skin using techniques discussed in connection with Figures 20A-20F. Thereafter, the freeze event happens while the skin- applicator interface is maintained at a temperature of about -2°C (indicated by the "*"). The temperature-controlled surface is then cooled to -10°C, and the freeze event is held at -10°C for a period of time (e.g., 1 minute, 2 minutes, etc.). Figure 21 shows a 1 minute holding period.
• a period of time e.g., 1 minute, 2 minutes, etc.
• the dermis can be thawed again by warming the applicator to -1 .5°C and again refrozen at -10°C while keeping the epidermis in a frozen non-thawed state.
• the thaw temperatures, warming rates, cooling rates, duration of freeze events, and refreeze temperatures can be selected based on the desired number of refreezes and severity of thermal injuries.
• the freezing rate is important because in a procedure in which extracellular space ice formation is triggered at -2°C, if the tissue is then slowly cooled to -10°C, there would be sufficient time for intracellular water to diffuse out and enter the extracellular space along a concentration gradient. This causes the intracellular solute concentration to rise and depress the intracellular melting/freezing temperature, thereby helping to reduce the probability of lethal intracellular ice formation at colder temperatures.
• the skin is triggered to freeze at -10°C (with a large supercooling window), there will not be enough time for cell dehydration, and thus no intracellular freezing point depression.
• treatment methods disclosed herein can provide complete control over all freeze-thaw parameters without allowing substantial skin supercooling that freezes larger amounts of tissue in faster time periods than procedures that do not use supercooling.
• a predetermined skin supercooling level with a predetermined duration can be achieved.
• a skin freeze can be triggered when a temperature of the applicator, coupling media, and skin is further cooled by, for example, a predetermined amount (e.g., less than 1 °C, 2°C, 3°C, or 4°C).
• Figure 22A shows a liquid coupling media that can serve as an insulator for ice inoculation of the skin, thereby allowing the skin to supercool.
• the applicator can be cooled a few degrees further to freeze the entire volume of coupling media. As shown in Figure 22B, this process shifts the temperature profile to the left of the freezing point of the coupling media. When ice crystals in the coupling media do reach the skin, the supercooled skin can freeze immediately or in a short period of time.
• coupling media can be applied to the applicator and the skin.
• the applicator is cooled by ramping down a temperature of a temperature-controlled surface to freeze coupling media, and it is then heated by ramping up to -13°C. Holding the temperature at -13°C will ensure that at least a layer of frozen media remains in contact with the applicator.
• Coupling media in a liquid state is applied to the skin surface.
• the applicator is applied to the liquid coupling media on the skin and then cools the coupling media and the skin to freeze the target tissue.
• melting/freezing points can be selected which results in desired temperatures for supercooling the skin while providing both a thin layer of frozen coupling media (e.g., a frozen layer on the applicator surface) and a thin layer of liquid coupling media (e.g., a liquid layer on the skin surface).
• a thin layer of frozen coupling media e.g., a frozen layer on the applicator surface
• a thin layer of liquid coupling media e.g., a liquid layer on the skin surface
• Figure 24A shows a layer of frozen coupling media 231 carried by the applicator.
• a carrier in the form of a paper towel soaked with 26% by volume PG/water can be placed on the temperature-controlled surface 21 1 .
• the temperature-controlled surface 21 1 can be precooled to rapidly freeze the coupling media 231 once the paper towel is applied. In other procedures, coupling media is spread, sprayed, or otherwise applied directly to the temperature-controlled surface 21 1 .
• Figure 24B shows another carrier in the form of a paper towel soaked with 26% by volume PG/water (at room temperature) applied to the subject's skin.
• the layer of liquid coupling media 233 e.g., 26% PG/water
• the layer of liquid coupling media 233 can be thick enough to prevent direct contact between the frozen coupling media 231 and the subject's skin upon placement of the applicator. Additionally, the liquid coupling media 233 helps improve a patient's comfort when placing the frozen coupling media 231 upon the coupling media 233.
• the applicator can continuously or intermittently extract heat to gradually increase the volume of frozen coupling media for a holding period.
• Figure 24D shows the thickened layer of frozen coupling media 231 .
• the coupling media 233 contacting the skin can remain in a liquid state and remain near but below its freezing temperature of -1 1 .5°C.
• Figure 24E shows the freezing front 221 moving toward the skin surface as the coupling media is cooled.
• the coupling media in contact with the skin freezes, the supercooled skin will be inoculated and freeze rapidly over a period of a few seconds.
• the applicator temperature can be ramped down to a temperature of about -15°C, -14°C, or -13°C in order to freeze the entire coupling media volume (i.e. , coupling media 231 , 233), and thus trigger a freeze event in the skin.
• the freeze event can be triggered by a temperature a few degrees colder than the supercooling temperature.
• skin can be cooled to a supercooling temperature of -13°C while still being able to trigger a freeze at a temperature only slightly lower, such as -15°C.
• This "dive" temperature of 2 degrees is much smaller than those required by conventional techniques that do not use a coupling media containing ice crystals that contact the skin (which are of the order of about 10 degrees) and serves as a skin-ice inoculating agent for triggering a predictable freeze event.
• a smaller dive temperature can result in a larger supercooled volume, and at the time of the tissue freeze, the frozen volume will also be larger compared to a treatment with a larger dive temperature.
• the applicator can warm the tissue to inhibit or limit further disruption, injury, etc. Warming and cooling cycles can be repeated any number of times in any order to thermally affect the targeted tissue.
• Figure 24F shows the entire volume of coupling media at the applicator-skin interface and underlying tissue in a frozen state.
• the applicator can be cooled or heated to increase or decrease the volume of frozen tissue.
• Figure 25 is a plot of temperature versus time for supercooling and freezing tissue.
• the skin can be cooled to -20°C, and then a freeze is initiated at -25°C by selecting a 37% by volume PG gel that has a freezing point of -19°C.
• the applicator can rapidly warm the epidermis and hold it at a temperature sufficiently high enough to keep the epidermis unfrozen.
• the epidermis can be held at a temperature of 1 .5°C or 2°C. This maximizes the underlying dermal freeze exposure to increase dermal damage and limits or minimizes the epidermal freeze exposure to reduce epidermal damage. Accordingly, warming can be used to minimize, limit, or substantially prevent thermal injuries that lead to hypopigmentation (skin lightening), hyperpigmentation (skin darkening), and/or other undesirable effects.
• the skin can be cooled to a temperature above the freezing point of the coupling media in order to trigger a freeze event.
• tissue is supercooled at - 13°C with a coupling media that has a slightly warmer freezing temperature (e.g., a freezing temperature of -1 1 .5°C)
• the skin will not be inoculated at temperatures significantly warmer than -13°C.
• a higher temperature melting/freezing point can be achieved by dilution of the coupling media to a lower concentration of a freezing point depressant.
• the melting/freezing temperature of the coupling media can be raised a sufficient amount to trigger a freeze at a temperature well above the supercooling temperature.
• supercooling at time t1 can be accomplished by choosing a coupling media that has a freezing temperature lower than that at time t1 . After supercooling, the applicator temperature ramps up to a higher temperature at time t2. A volume of water can be delivered into the coupling media to dilute it, ensuring that the diluted coupling media has a freezing point warmer than the temperature at t2. This will trigger a freeze in the diluted coupling media to quickly trigger a skin freeze.
• a relatively warm on-command freeze in the supercooled diluted coupling media can be triggered using, for example, energy (e.g., ultrasound), low temperature probes (e.g., an extremely small cold finger probe), and/or an INA.
• Figure 26 is a plot of temperature versus time for a procedure that cycles twice to supercool tissue and then triggers a freeze.
• tissue can be cycled between two temperatures (e.g., -10°C and -20°C) to supercool targeted tissue.
• a freeze event is triggered while at the higher temperature (e.g., -10°C) or another suitable temperature.
• the freezing point of the coupling media can be selected to ensure that the coupling media does not freeze during a supercooling cycle.
• the coupling media can comprise at least 39% by volume PG that has a freezing point of -20.5°C so that the coupling media does not freeze during a supercool cycle at -20°C to avoid initiating a premature skin freeze.
• the temperature of the applicator can be raised to a higher temperature (e.g., -10°C) suitable for ice inoculation.
• a substance such as cold water at 1 °C, can be infused through the applicator to dilute the coupling media.
• the temperature and flow rate of the water can be selected such that the diluted coupling media has a freezing point warmer than a predetermined value.
• the diluted coupling media can have freezing point higher than about -10°C for freeze inoculation at about -10°C.
• Figures 27A-27C show an applicator and a coupling media.
• liquid coupling media is located along a temperature-controlled surface 243 of the applicator.
• Conduits, plates, and/or fluidic components of the applicator can have one or more thermally insulating coatings, layers, etc., to avoid unwanted freeze during infusion because the cold applicator plate can be at relatively low temperatures, for example, less than -5°C, -10°C, or -12°C.
• the applicator can include thermal elements (e.g., heating elements) for warming the diluting liquid, coolant (e.g., coolant delivered through the applicator), and other working fluids.
• Figure 27B shows the applicator and diluted coupling media.
• a diluting liquid has passed through the conduit to dilute the coupling media.
• the amount of diluting liquid can be selected to achieve the desired coupling media concentration.
• the coupling media can freeze as the applicator is cooled and the temperature of the coupling media stabilizes at a predetermined or target temperature, such as -8°C, - 10°C, or -12°C.
• An INA can be incorporated into the coupling media or into the infused liquid to promote freezing.
• Ultrasound can be used to initiate, promote, and/or control a freeze event.
• cold water can be delivered into an ultrasound chamber and, in some embodiments, can contact an upper surface of the liquid coupling media.
• Cooling elements, cold plates, or other components of the applicator can cool the water surrounding an ultrasound probe, which can be activated to deliver ultrasound energy to the cooled water to cause freezing.
• Ultrasonic agitation e.g., ultrasonic agitation with an appropriate frequency, power, etc.
• One or more INAs can be incorporated into the coupling media before, during, and/or after applying the coupling media to the patient. Dilution of the coupling media to a point where its diluted melting temperature is above its actual temperature will cause the diluted coupling media to freeze, which in turn will cause freezing of the skin.
• Figures 28-31 show treatments that can involve supercooling. Supercool cycling can cover a broad temperature range, with the coldest desired supercool temperature oftentimes being too cold to use as a freezing temperature because it would cause excess damage to the epidermis. Coupling media that remains in a liquid state during the supercool cycle will often not allow ice inoculation because the supercooling temperature range is above the freezing point of the coupling media.
• epidermal temperatures can be sufficiently warm to inhibit, limit, or substantially prevent hypopigmentation, hyperpigmentation, or other undesirable effects.
• Dilution also enables supercool cycling at relatively low temperatures (e.g., -10°C, -15°C, -20°C) and tissue freezes at relatively high temperatures (e.g., - 10°C, -5°C, -4°C, -3°C, or -2°C) to enhance or maximize damage to targeted tissue and limit or minimize damage to non-targeted tissue.
• the targeted tissue can be tissue in the dermis and/or lower skin layers, and the non-targeted issue can be the epidermis or shallow tissue.
• Figure 28 shows an applicator 261 , media 262 with an INA, and a coupling layer 263.
• An INA can be placed in direct contact with the skin surface to facilitate a predictable freeze of the skin.
• the INA is placed in direct contact with a cooling surface of the applicator.
• the media 262 can include one or more I NAs (e.g., SNOMAX®/water mix).
• the coupling layer 263 can include cellulose-derived layer and solution, such as water, and can be in direct contact with a treatment site.
• the INA can be applied using a thin layer (e.g., paper) soaked with an INA coupling agent, mixed with a gel like substance, delivered via a delivery instrument (e.g., syringe), or sprayed over the surface.
• a delivery instrument e.g., syringe
• Figure 29 shows a plot of temperature versus time of a temperature profile for triggering ice nucleation via INAs. Tissue can be supercooled to a temperature above the INA activation temperature.
• the temperature of the INA is then lowered to its activation temperature to initiate ice nucleation to produce a partial or total freeze event (indicated by the "*") propagating into and through the skin.
• the cycle can be completed by holding a temperature of the applicator to permit the growth of ice crystals at the treatment site. After completing the cycle, the temperature of the applicator can be gradually raised at a desired thaw rate to warm the skin.
• Figure 30 shows an applicator and an INA applied to a treatment site.
• the INA can be delivered into coupling media 271 , onto a subject's skin surface, and/or into the skin to predictably trigger ice nucleation.
• the applicator can include embedded fluidics for controllably delivering the INA to the interface between the applicator and the subject's skin.
• the infused INA can be at a specific treatment temperature or within a predetermined temperature range to inhibit ice nucleation within, for example, coupling media at the interface or the tissue itself.
• the INA is sprayed or otherwise delivered to the coupling media or the subject's skin. In some procedures, the applicator cools the coupling media and the subject's skin.
• the applicator can be lifted off the coupling media, and the INA can be sprayed onto the cooled coupling media. After spraying the INA, the applicator can be reapplied to the treatment site to continue cooling the INA, coupling media, and tissue. Needles, rollers, and other delivery instruments can be used to apply one or more INAs. Other techniques can be used to provide INA infusion through the coupling media, as well as on or into the coupling media and/or subject's tissue, etc.
• Figure 31 shows a plot of temperature versus time for delivering an INA for nucleation.
• the INA can be delivered to a treatment site, which can be at or below the INAs activation temperature (indicated by a dashed line), at a specific time to initiate nucleation. As indicated by the arrow, the INA can be infused to initiate the freeze event. Accordingly, the INAs activation temperature can be selected to trigger a controlled freeze event.
• Various techniques can be used to protect non-targeted tissue while affecting targeted tissue volumes and/or specific structures within, for example, the epidermis, dermis, subcutaneous tissue, etc.
• the targeted structures can include, without limitation, hair (e.g., hair follicles), skin appendages (e.g., sweat glands, sebaceous glands, etc.), nerves, and/or dermal components, such as collagen, elastin, or blood microvascularity.
• Targeted structures can be affected while inhibiting, preventing, or substantially eliminating unwanted side effects. Because appendages and other cells/structures may have different lethal temperatures, a multi-step temperature profile can be used to target specific tissue and/or structures.
• preserving the non-targeted tissue, such as the epidermis, from undue injury or damage could be beneficial in to prevent, for example, pigment changes and/or scarring, as well as to promote healing.
• Freezing the epidermis at a different temperature than the underlying dermis can be achieved by using the characteristic activation temperature of the INA and by intentionally supercooling the dermis at lower temperatures before applying the INA.
• the epidermis can be at a higher temperature to inhibit, limit, or substantially prevent permanent thermal injuries to the epidermis.
• Some embodiments of the technology include methods of using linked polymers containing water, a crosslinked polymer that contains water, optionally an INA, and/or optionally a freezing point depressant for controlled freeze of skin tissue.
• the polymer can be a hydrogel for use for controlled freezing of skin tissue.
• the hydrogel can be an effective initiator of a freeze event. As hydrogel freezes, it can provide initial seeds or crystal sites to inoculate and freeze tissue, thus catalyzing a controlled predictable freeze at specific temperature(s) in skin.
• Figures 32A-32D show IR imaging of tissue freeze inoculation using a hydrogel with supercooled tissue.
• Figure 32A shows skin tissue (dashed area) over two hydrogels (left and right halves) and a cooling plate overlying the hydrogels.
• Figure 32B shows freezing at a lower left portion.
• Figure 32C shows freeze propagation along most of the left hydrogel demonstrating ice inoculation.
• Figure 32D shows freeze propagation through both hydrogels.
• the skin tissue at the area indicated by dashed lines contacts two half-sheets of hydrogel.
• a hydrogel sheet with no PG or other freezing point depressant is located to the left of the vertical line, and a hydrogel sheet with about 50% by volume PG is located to the right of the vertical line.
• a rectangular cooling plate is located on the hydrogel sheets. The skin surface is in direct contact with both hydrogels, which in turn are in direct contact with the cooling plate. In this manner, the hydrogels can be held firmly between the patient and the applicator.
• FIG. 32B The images were generated after a few minutes of supercooling the tissue.
• the temperature of the supercooled tissue was lowered to a trigger temperature to trigger a freeze (illustrated in lighter color) in the non-PG hydrogel, illustrated on the left side of Figure 32B.
• Figures 32B and 32C show freeze propagation caused using only a hydrogel.
• the right half of Figure 32B shows a section of the 50% by volume PG hydrogel and adjacent skin that has not been frozen.
• Figure 32C shows the freeze propagating across the hydrogel, through the tissue, and toward the hydrogel with the temperature depressant. This shows that varying concentrations of PG or other freezing point depressants can be included in the hydrogel to lower the hydrogel's melting/freezing temperature to a desired value lower than 0°C.
• hydrogels used in combination with an INA provide the capability for a controlled freeze at subzero temperatures, including temperatures close to 0°C (or lower when used in conjunction with a freezing point depressant) in a more predictable manner.
• Figures 33A-33D are IR images showing tissue freeze inoculation using combined materials and the effect over time of placing an INA (e.g., SNOMAX® or other suitable INA derived from bacterium Pseudomonas Syringae) on a supercooled hydrogel to trigger a freeze.
• Figure 33A shows placement of a grain of an INA on a supercooled hydrogel.
• Figure 33B shows an INA inoculating the hydrogel and a freeze starting to propagate around the INA.
• Figure 33C shows freeze propagating across the hydrogel to the tissue demonstrating ice inoculation of skin.
• Figure 33D shows the completed freeze propagation.
• the Figures 33A-33D show the feasibility of using an INA as a seed for inoculating a controlled freeze in skin tissue. Details of Figures 33A-33D are discussed below.
• Figure 33A shows unfrozen hydrogel and the INA being placed near an edge of a cooling plate (indicated by dashed lines) while the cooling plate cools the tissue.
• the INA can initiate the freezing process by serving as an ice nucleator and can raise the predictable freezing temperature of water to about -3°C.
• the melting/freezing temperature of water is 0°C
• water has the tendency to supercool, so its freezing temperature is often far lower than 0°C or -3°C when an INA has not been used.
• the I NA can initiate the freezing process by serving as an ice nucleator and can raise the predictable freezing temperature of water to about -3°C.
• the I NA can be selected to raise the predictable freezing temperature of water to other desired temperatures.
• an INA e.g., one skilled in the art can choose appropriate agents (e.g., organic or inorganic derived agents) to use for specific desired temperature(s) and to be delivered at specific times for a specific treatment purpose.
• agents e.g., organic or inorganic derived agents
• Different techniques can be used to incorporate I NA into hydrogels.
• an INA can be sandwiched between layers of a hydrogel so as to be totally contained and encapsulated therein and so as to never come in contact with skin or tissue.
• An encapsulant can be disrupted, destroyed, or otherwise altered to release the INA.
• a cooling plate of an applicator can deliver the INA to the hydrogel via one or more needles, exit ports, or other delivery means.
• the INA can be applied at a single location or multiple locations, or it can be mixed into the hydrogel compound. Additionally, the INA can be inside a micrometric wall made of hard or soft soluble film so as to avoid direct skin contact and have controlled degradation by passive or active means. Additionally, the INA can be injected or delivered into or onto the skin.
• Figure 33B shows the tissue after the freeze has propagated away from the INA.
• the frozen material is illustrated by a lighter color against a darker background color, which illustrates non-frozen tissue.
• Figure 33C shows freeze propagating across the hydrogel facing the cooling plate.
• Figure 33D shows the completed freeze propagation to freeze all of the skin directly contacting the hydrogel.
• FIGs 34A and 34B are cross-sectional views of the cooling applicator applied to a treatment site.
• a hydrogel is located between the applicator and the subject's skin.
• the cooling applicator can be disposed over a protective layer in the form of a thin cover layer.
• the protective layer can be a liner or other component for preventing cross-contamination or soiling by the hydrogel.
• Figure 34B shows a hydrogel and an INA located between the applicator and the subject's skin.
• the I NA can be a liquid, gel, cream, preformed sheet or layer located along a surface of the hydrogel.
• the INA can be located at the hydrogel-applicator interface.
• the hydrogel and/or hydrogel/INA/freezing point depressant can be selected to melt/freeze at a specific temperature designed into its formulation.
• the hydrogel of Figures 34A and 34B can be formulated to have a constituent ratio of water-monomer-crosslinker and/or other chemicals, such as one or more INAs, freezing point depressants, etc., to achieve a specific freezing point (or close range of temperatures) that may or may not allow for skin supercooling.
• An INA can have a known activation temperature (natural freezing point) and can be in solid form (i.e., powder) or mix solution with a desired concentration to create a predictable and consistent skin freeze. With such thermal coupling materials or compounds, a desired treatment temperature protocol or algorithm can be implemented to allow for supercooling if desired, or no supercooling if desired, and to allow for predictable and controlled freezing at preferred temperatures and times.
• Figure 35 is a plot of temperature versus time for triggering a freeze agent in accordance with embodiments of the disclosed technology.
• the temperature profile, protocol, and/or algorithm for triggering one more freezes allows supercooling of tissue at temperatures allowed by the hydrogel or hydrogel/INA.
• the temperature of the targeted tissue can be kept in the supercooling temperature range for a supercooling period.
• the temperature of the hydrogel is then lowered to a freezing temperature to cause ice nucleation of the hydrogel or materials.
• the underlying targeted tissue can be at or slightly warmer than the hydrogel.
• both the hydrogel and targeted tissue are supercooled while the temperature of the temperature-controlled surface of the applicator is held generally constant.
• FIG. 36 shows an applicator positioned to produce a controlled freeze in a coupling media delivering the agent onto a surface of the coupling media, into the coupling media, or at another suitable location for initiating a freeze event in the coupling media.
• the applicator can include one or more needles (e.g., a microneedle array), fluid components (e.g., conduits, pumps, valves), reservoirs (e.g., reservoirs holding coupling media), or the like.
• the agent is delivered out an exit port at the bottom of a cooling plate of the applicator.
• Figure 37 shows a cooling applicator with an external nucleating element configured to initiate a freeze event external to an applicator-hydrogel interface.
• the external nucleating element can include one or more energy emitting elements capable of initiating a freeze event.
• an external nucleating element delivers energy (e.g., ultrasound energy, RF energy, etc.) to an edge region of the coupling agent to produce a freeze, which propagates through the coupling agent, including a region of the coupling agent directly between the cooling applicator and the tissue site.
• a separate nucleating instrument can initiate nucleation and can be a probe with a nucleating element.
• FIG 38 is a cross-sectional view of a cooling applicator that provides energy-based activation.
• Coupling media, hydrogels, hydrogel/INA mixtures, or other materials for generating a controlled freeze can be located between the cooling applicator and the treatment site.
• an encapsulated ice nucleator can be part of or located within a layer of coupling media.
• Energy can break the encapsulation to release the ice nucleator at a desired time. This can cause a freeze event that spreads through the coupling media and into the surface of the skin. Once ice crystals contact the surface of the skin, the freeze can propagate through the skin.
• the actuation energy can be, without limitation, mechanical energy (e.g., vibrations, ultrasound, etc.), electrical energy, and/or electromagnetic radiation (e.g., light).
• Figures 39 shows a temperature profile for supercooling skin prior to initiating a freeze event. Freeze activation can be controllably initiated to control freeze onset while a temperature-controlled surface of the applicator and/or the target tissue is held at a constant steady state temperature. It may be desirable to supercool and freeze skin and subcutaneous tissue for a specific time and at a specific temperature (or temperature range) to allow controlled supercooling of a tissue volume that is sufficiently large to cause a widespread freeze upon tissue inoculation.
• tissue and/or affect specific structures within the dermis and subcutaneous tissue like hair, skin appendages, nerves, dermal components such as collagen, elastin, or blood microvascularity but at the same time to preserve the epidermis.
• appendages and other cells/structures may have a different lethal or injury temperature, a multi-step temperature profile may be needed.
• preserving the epidermis could be beneficial in the prevention of skin pigment changes and skin scarring.
• preserving the epidermis can result in more favorable healing and fewer side effects. Freezing the epidermis at a different temperature than the underlying dermis is possible by using the aforementioned techniques.
• the skin bulk tissue can be supercooled at low temperatures and then the temperature of the epidermis can be raised before, for example, delivering the INA or activating nucleation.
• Epidermal sensitivity is reduced when the epidermis freezes at a temperature of around -5°C or higher. If freezing below those temperatures occurs, melanocytes and/or their melanin production in the epidermis may get unduly altered causing pigmentation. So, according to some embodiments of the disclosed technology, temperature protocols can be used that cause freezing of the epidermis at or above -5°C.
• Figure 40 is a plot of temperature versus time where, after supercooling and before freezing, a temperature of the applicator is adjusted to warm the epidermis such that the applicator and/or epidermis is at a higher temperature (e.g., -6°C, -5°C, -4°C, etc.) than the supercooling temperature.
• a freeze event is generated.
• the temperature profile shows activation or delivery of INAs at a warmer activation temperature suitable for protecting tissue, such as the epidermal or upper layers of the skin.
• the warming rate, activation temperature, and time period for the activation temperature can be selected based on the desired tissue protection and affects to the targeted tissue.
• the activation holding time period can be increased or decreased to increase or decrease protection of the epidermis.
• Figure 41 shows a plot of temperature versus time for a cooling protocol and three cross-sectional views of an applicator and skin tissue temperature distributions.
• a temperature-controlled surface of an applicator can be held at -10°C for 5 minutes (for supercooling) and then increased at a desired rate (e.g., 2°C/s, 2.5°C/s, etc.).
• Computational modeling (COMSOL) was used to generate the results. The model was a three-dimensional bioheat transfer model for the treatment of skin using a cooling applicator and was used to generate plots discussed herein.
• the images show temperature distributions in tissue related to the temperature profile step change of the temperature-controlled surface from -10°C to - 4°C.
• the epidermis will freeze at a more optimal temperature (>-5°C) but with a superior extent of the skin freeze down to a depth of approximately 2 mm.
• Figure 44 shows one method of creating a tissue freeze using a device positioned within a subject.
• the device can be a needle that injects a substance at a specific location.
• An interior surface of the needle can be coated to facilitate delivery of the substance.
• the exterior surface of the needle can be coated with an agent or substance for treating tissue, targeted structures, etc.
• Other devices can be inserted into the subject to produce freeze events.
• the injected substance can include, without limitation, hydrogel, hydrogel/INA, partially frozen water, ice nucleators, combinations thereof, or the like.
• An advantage of injecting an ice crystal or substance (e.g., an INA) that will create an ice crystal is that a freeze event will occur at a specific region.
• the freeze event can be initiated in the dermis or other lower tissue layer and not in the epidermis. This limits or minimizes damage to the epidermis.
• the epidermis can be warmed to a temperature close to or above its melting/freeze temperature.
• a freeze event can be initiated in tissue below the dermis, such as in subcutaneous tissue.
• the same or different needle can inject additional substances into the tissue.
• the additional substances can include cryoprotective agents, liquids (e.g., warm water or saline), or other substances that can effect therapy.
• a first substance can be delivered into tissue to create a first freeze event
• a second substance can be delivered into other tissue to produce a second freeze event.
• the first substance can be adapted to completely freeze at a first target region
• the second substance can be adapted to produce a partial freeze event at a second target region spaced apart from the first target region.
• Different levels of freezing and severity of thermal injury can be achieved even though the first and second target regions are at the same temperature.
• the first and second target regions can be at different temperatures, and the first and second substances can be selected based on those temperatures. In this manner, different types of freeze events can be generated at different locations.
• substances with thermal coupling materials or nucleators having freezing points at higher temperatures than a freezing point of fluid in skin tissue may be used synergistically with the treatment cycle to produce an intentional freeze of the material and sequentially trigger freezing propagation into the skin at yet higher temperatures.
• Non-targeted tissue can be warmed by the applicator (e.g., via conduction), injected warm liquid, and/or energy (e.g., RF energy).
• Warming cycles can be performed to warm the epidermis immediately after producing a freeze event that injures target structures, such as sebaceous gland. This can help prevent visible alterations (e.g., hyperpigmentation, hypopigmentation, etc.) to the epidermis.
• the injectable substance can be delivered to and around the sebaceous gland and freeze event can then be triggered by a temperature dive, dilution, energy, etc.
• FIG. 45 is a flow diagram illustrating a method 350 in accordance with an aspect of the present technology.
• coupling media can be applied to the subject.
• an applicator cools the tissue to a temperature suitable for a freeze event.
• a skin surface can be lowered to a first temperature between about -2°C and -40°C to supercool shallow tissue.
• the first temperature can be a temperature between -5°C and -15°C, -5°C and -20°C, -10°C and -30°C, or other suitable temperature range below a freezing temperature.
• the surface of the human subject's skin is heated an amount sufficient to raise the skin surface temperature from the first temperature to a second temperature, which can be a non-supercooled temperature, while the targeted region remains in the supercooled state.
• a second temperature which can be a non-supercooled temperature
• the epidermis can be heated to a temperature higher than about 0°C, higher than about 5°C, higher than about 10°C, higher than about 20°C, higher than about 30°C, or higher than about 35°C.
• the device of Figure 44 can cause nucleation at the target region to cause at least some fluid and cells in the supercooled tissue to at least partially or totally freeze. Warmed cells residing at the surface of the human subject's skin do not freeze. As such, cells at the skin surface can be protected without using a chemical cryoprotectant. However, chemical cryoprotectants can be used to inhibit or limit hyperpigmentation or hypopigmentation.
• a probe can be inserted into the subject to cause nucleation of the supercooled tissue via a mechanical perturbation, ultrasound, or other suitable nucleation initiator. The freeze event can cause at least partial crystallization of a plurality of gland cells in the target region.
• the illustrated device of Figure 44 is positioned to produce a freeze event that causes crystallization of cells in the sebaceous gland.
• the supercooled tissue can be maintained in the frozen state for a predetermined period of time longer than, for example, about 10 seconds, 12 seconds, 15 seconds, 20 seconds, or other suitable length of time sufficient to treat acne, improve a quality of hair, treat hyperhidrosis, etc.
• the skin is cooled/heated to keep the targeted tissue in at least a partially or totally frozen state for the predetermined time longer than about 10 seconds, 12 seconds, 15 seconds, or 20 seconds.
• Heat can be applied to warm epidermal cells to a temperature above freezing while glands in the dermis are at or near the supercooled temperature.
• the step of applying heat can include warming a portion of most of the epidermal layer under the treatment device to a temperature above about 0°C, about 5°C, about 10°C, about 20°C, about 25°C, or about 32°C. Warming can be accomplished before, during, or after the freeze event.
• the subject's body heat, warm blood, or other mechanisms can naturally heat the epidermis to avoid or limit freeze damage to those cells.
• Applicators can include one or more electrodes, transducers, or other energy-emitting elements.
• an applicator can cool the skin surface shown in Figure 44 to supercool the tissue, including the dermis.
• the applicator can deliver RF energy or focused electrical currents to the underlying non-targeted subcutaneous tissue to localize supercooling to dermal tissue. A freeze event is then initiated in the supercooled dermal tissue.
• the methods disclosed herein are capable of supercooling tissue without initiating nucleation by cooling tissue at a relatively slow rate (e.g., the temperature profile can cause a slow cooling of the tissue at the target region).
• the rate of cooling can be either equal to, slower or faster than about 0.5°C, 1 °C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C or 10°C per minute.
• a preferred rate of cooling is about either 2°C, 4°C, or 6°C per minute.
• a treatment device can apply a generally constant pressure during cooling to the supercooled temperature range to avoid pressure changes that would cause inadvertent nucleation.
• the targeted tissue can be cooled while the patient is held still (e.g., without movement of the treatment site) to avoid mechanically disturbing the supercooled tissue and unintentionally causing crystallization.
• Figure 46 is a schematic block diagram illustrating subcomponents of a computing device in the form of a controller suitable for the system 100 of Figure 3 in accordance with an embodiment of the disclosure.
• the computing device 700 can include a processor 701 , a memory 702 (e.g. , SRAM, DRAM, flash, or other memory devices), input/output devices 703, and/or subsystems and other components 704.
• the computing device 700 can perform any of a wide variety of computing processing, storage, sensing, imaging, and/or other functions.
• Components of the computing device 700 may be housed in a single unit or distributed over multiple, interconnected units (e.g., through a communications network).
• the components of the computing device 700 can accordingly include local and/or remote memory storage devices and any of a wide variety of computer-readable media.
• the processor 701 can include a plurality of functional modules 706, such as software modules, for execution by the processor 701 .
• the various implementations of source code i.e., in a conventional programming language
• the modules 706 of the processor can include an input module 708, a database module 710, a process module 712, an output module 714, and, optionally, a display module 716.
• the input module 708 accepts an operator input 719 via the one or more input/output devices described above with respect to Figure 3, and communicates the accepted information or selections to other components for further processing.
• the database module 710 organizes records, including patient records, treatment data sets, treatment profiles and operating records and other operator activities, and facilitates storing and retrieving of these records to and from a data storage device (e.g., internal memory 702, an external database, etc.). Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, distributed database, etc.
• the process module 712 can generate control variables based on sensor readings 718 from sensors (e.g., sensor 167 of Figure 2) and/or other data sources, and the output module 714 can communicate operator input to external computing devices and control variables to the controller 1 14 ( Figure 3).
• the output signals 720 can be used to control one or more applicators applied to the patient. In some embodiments, the output signals 720 can be commands for controlling applicators.
• the display module 816 can be configured to convert and transmit processing parameters, sensor readings 818, output signals 720, input data, treatment profiles, and prescribed operational parameters through one or more connected display devices, such as a display screen, printer, speaker system, etc.
• a suitable display module 716 may include a video driver that enables the controller 1 14 to display the sensor readings 718 or other status of treatment progression.
• the processor 701 can be a standard central processing unit or a secure processor.
• Secure processors can be special- purpose processors (e.g., reduced instruction set processor) that can withstand sophisticated attacks that attempt to extract data or programming logic.
• the secure processors may not have debugging pins that enable an external debugger to monitor the secure processor's execution or registers.
• the system may employ a secure field programmable gate array, a smartcard, or other secure devices.
• the memory 702 can be standard memory, secure memory, or a combination of both memory types. By employing a secure processor and/or secure memory, the system can ensure that data and instructions are both highly secure and sensitive operations such as decryption are shielded from observation.
• the memory 702 can contain executable instructions for cooling the surface of the subject's skin to a temperature and controlling treatment devices in response to, for example, detection of supercooling, a partial or complete freeze event, movement of the applicator (e.g., applicator pull off), or the like.
• the memory 702 can include nucleation instructions that, when executed, cause the controller to command an applicator to alter the composition of a coupling media, inject nucleation initiator, etc.
• the memory 702 can include thawing instructions that, when executed, causes the controller to control the applicator to heat tissue.
• the stored instructions can be executed to control the applicators to perform the methods disclosed herein without causing undesired effects, such as significantly lightening or darkening skin one of more days after the freeze event ends.
• the instructions can be modified based on patient information and treatments to be performed.
• Other instructions and algorithms can be stored and executed to perform the methods disclosed herein.
• the controller 1 14 is programmed to cause the applicator to create or maintain at least one ice crystal and to induce a freeze event.
• the memory 702 can contain instructions that when executed cause the applicator to operate to cause one or more ice crystals to contact the subject skin so as to induce a freeze event.
• the memory 702 contains instructions that when executed by the processor 701 cause the applicator to be a suitable temperature for supercooling target tissue and for freezing the skin without lowering a temperature of the temperature-controlled surface below a particular level.
• the instructions can be used to control or communicate with components of applicators. These components can include, without limitation, one or more thermoelectric elements, fluid elements, energy-emitting elements, and sensors.
• thermoelectric elements can be Peltier devices capable of selectively cooling or heating the tissue.
• the fluid elements can be cooling channels, conduits, or other fluid elements through which fluid can flow to heat and/or cool tissue.
• the energy emitting elements can be radiofrequency electrodes, ultrasound electrodes, or other elements capable of delivering energy to control freezing, warm tissue, or the like.
• the treatment systems, applicators, and methods of treatment can be used to treat acne, hyperhidrosis, wrinkles, subcutaneous tissue, structures (e.g., structures in the epidermis, dermis, subcutaneous fat, muscle, nerve tissue, etc.), and so on.
• Methods for cooling tissue and related devices and systems in accordance with embodiments of the present invention can at least partially address one or more problems associated with conventional technologies as discussed above and/or other problems whether or not such problems are stated herein.
• Methods for affecting skin of a human subject's body include positioning an applicator of a cooling apparatus on the subject and removing heat from a treatment site to affect the appearance of the subject's skin with or without causing an appreciable reduction of subcutaneous adipose tissue.
• Acne along the face can be treated without causing any reduction of subcutaneous adipose tissue wherein acne along the back can be treated while reducing of subcutaneous adipose tissue.
• Systems, components, and techniques for reducing subcutaneous adipose tissue are disclosed in U.S. Patent No. 7,367,341 titled "METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING" to Anderson et al., U.S. Patent Publication No.
• a sufficient amount of thermal energy is removed from the treatment site so as to tighten skin at the treatment site, or in further embodiments, to alter the tissue between a surface of the skin and subcutaneous lipid-rich cells of the subject's body.
• tissue is cooled to induce fibrosis that increases the firmness of tissue at the treatment site. Fibrosis can be induced in the epidermis, dermis, and/or subcutaneous tissue. Vacuum applicators can stretch, stress, and/or mechanically alter skin to increase damage and fibrosis in the skin, affect glands, control freeze events (including initiating freeze events), etc.

Landscapes

• Health & Medical Sciences (AREA)
• Vascular Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Thermal Sciences (AREA)
• Physics & Mathematics (AREA)
• Thermotherapy And Cooling Therapy Devices (AREA)
• Surgical Instruments (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=58692637

Family Applications (1)

Country Status (8)

Families Citing this family (33)

Family Cites Families (47)

• 2017
  • 2017-04-27 KR KR1020187035845A patent/KR20190005981A/ko not_active Application Discontinuation
  • 2017-04-27 EP EP17722615.6A patent/EP3454800A1/en not_active Withdrawn
  • 2017-04-27 WO PCT/US2017/029887 patent/WO2017196548A1/en unknown
  • 2017-04-27 JP JP2018559772A patent/JP2019514616A/ja active Pending
  • 2017-04-27 AU AU2017264512A patent/AU2017264512A1/en not_active Abandoned
  • 2017-04-27 CA CA3023821A patent/CA3023821A1/en not_active Abandoned
  • 2017-04-27 CN CN201780038438.0A patent/CN109310516A/zh active Pending
  • 2017-04-27 BR BR112018073275-3A patent/BR112018073275A2/pt not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events